We discuss the presence of anti-keratin antibodies (AKA) of the IgG class in patients with defined juvenile idiopathic arthritis (JIA). An indirect immunofluorescence test and rat oesophagus substrate was used for the detection and quantification of AKA antibodies in patients´ sera. Overall 33/60 patients with JIA had sera positive for AKA (55 %, P = 0,0001) ranging from 1:10 to 1:160 dilutions. Following idiopathic arthritis of childhood classification criteria AKA occurred in 2/7 patients with systemic disease (28,6 %), in 13/30 patients with RF negative polyarthritis (43,3 %, P = 0,008) and in 15/18 RF positive polyarthritis (83,3 %, P = 0,000002). AKA were also found in a small cohort of patients with oligoarthritis (1/3) and psoriatic arthritis (2/2). AKA positivity occurred in 3/26 healthy controls at a 1:20 dilution. The presence of AKA was correlated as well as with the severity of the disease. Our study revealed that AKA was present overall in 18/29 patients (62%) with severe JIA and in 12/26 patients (46,2 %) with non-severe disease, however this did not reach statistical significance (P = 0,18). We also observed that AKA remained positive regardless of disease activity. AKA were detectable in 55,6 % patients with active JIA and in 48,6 % patients in the complete or near remission. Acknowledgement: This research was supported by a European Commission (Acronym: EUROBANK, contract no: QOL-2000-14.1), web site http://www.ncl.ac.uk and by grant of 2nd Medical Faculty, Charles University in Prague, VZ no. 111300003.
RF pos (n = 31) 7 (23%) 4 (13%) 6 (19%) 5 (16%) 9 (29%) RF neg (n = 38) 23 (60%) 6 (16%) 3 (8%) 4 (11%) 2 (5%)
The clinical sensitivity of the anti-CCP test in our RA patients was 58%, which is lower than previously reported (68%). The discrepancy might partially be due to different calculation of the results. We believe that the introduction of polynomal standard curve could contribute to a more consistent validation of samples exhibiting OD bellow the lowest calibrator.
Our results support the idea that anti-CCP are of diagnostic value especially in RF neg patients.
Introduction:
The presence of autoantibodies directed to citrullinated antigens in serum is highly specific for RA. The aim of this study was to compare anti-CCP concentrations in paired serum/SF samples of patients with RA and to investigate whether this is associated with the expression of citrullinated antigens in RA synovium and to study the nature of these antigens. Methods: A recombinant single-chain variable fragment (scFv) monoclonal antibody was selected against a cyclic citrullinated peptide (CCP) from a patient antibody-fragment phage-display library. This scFv and patient antibodies affinity purified with CCP, were both used for immunohistochemical staining of synovial cryostat sections of RA (30) and control patients (OA (13), ReA (9), and other arthritides (28)). In addition, rabbit anti-citrullin antibodies (Biogenesis) were used for immunohistochemistry of synovial cryostat sections of RA (14), and control patients (OA (10), ReA (7), and other arthritides (23)). IgG anti CCP titers were calculated with the quantitative Rapscan RA ELISA kit (Eurodiagnostica). Total IgG concentrations were determined on a cobas Fara-2 centrifugal analyzer.
Results: Citrullin containing antigens were observed in synovial cryostat sections of anti-CCP positive and negative patients. Staining with ScFv monoclonal antibody was noted in synovial lining cells and in (peri)vascular areas in 13/30 RA patients, 7/13 OA patients, 5/9 ReA patients, and 12/28 other arthritis patients. CCP positivity was on average similar in all diagnostic groups. Staining was absent in the negative controls using a control scFv antibody. Staining with rabbit anti-citrullin polyclonal antibody was noted in 8/14 RA patients, 3/10 OA patients, 2/7 ReA patients, and 6/23 other arthritides. However, controls using irrelevant rabbit antibodies were also positive in some patients in all groups. Anti-CCP concentrations (expressed in Units per mg total IgG) were on average 1.34 times higher in SF compared to serum (n = 20, P < 0.05) or 1.37 when only positive samples were included (n = 11, P < 0.05) Conclusion: Citrullinated antigens are present in the synovia of both RA and control patients with similar prevalence. The presence of anti-CCP autoantibodies in serum is not associated with the expression of citrullinated antigens in the synovium. The identity of the citrullinated antigens and potential differences between RA and control synovia remain to be identified.
Anti-filaggrin autoantibodies (AFA) are highly specific markers for rheumatoid arthritis (RA) and can be detected by immunoblotting using human epidermal protein extracts. Furthermore, it was demonstrated that citrullination of the filaggrin epitopes is crucial for epitope recognition and that citrullinated peptides are also recognized by these specific autoantibodies. Based on these data, a line immunoassay (LIA) was developed containing as individual markers in vitro citrullinated recombinant filaggrin and two citrullinated synthetic peptides. Firstly, a comparison was made between this prototype LIA and the AFA blot using natural filaggrin. A blind serum panel consisting of 25 early RA, 25 longstanding RA, and 25 disease controls was selected. Results showed a similar performance of both tests at a specificity level of 95%, while the LIA proved significantly better (P = 0.035) than the AFA blot at 99% specificity. At the latter specificity level, 2 out of 17 RF negative samples were retrieved on LIA but not on Western blot. The LIA was further evaluated on sera obtained from 335 RA patients and 254 patients with non-RA rheumatological disorders in a retrospective study. The overall sensitivity of the LIA including three markers (LIA3) was 65.1% versus 61.8% if only the reactivity towards the citrullinated peptides was considered (LIA2). The specificity of LIA3 was 97.6% versus 98.4% for LIA2, which correlates with an estimated positive predictive value (PPV) of 87.3% for LIA3 and 90.7% for LIA2. Thirty-seven percent (30/81) of the RFnegative RA samples proved LIA2-positive, while 52 out of 55 RF positive control samples were negative for anti-filaggrin. Higher specificity and sensitivity was obtained for LIA2 in comparison with anti-RA33 immunoblot, whereas good agreement could be observed with anti-keratin antibody (AKA) testing.
In conclusion, anti-filaggrin autoantibodies can be readily detected by a LIA test based on citrullinated peptides, resulting in a high specificity and hence high PPV for RA. The assay can serve as a user-friendly alternative for AKA immunofluorescent and immunoblot techniques. Together with the RF complementarity, this test provides a valuable tool in the differential diagnosis of RA.
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ELISA detection of antifilaggrin autoantibodies onto deiminated recombinant rat filaggrin: a highly effective test for the diagnosis of rheumatoid arthritis C Vincent*, M Sebbag*, M Arnaud † , L Nogueira*, S ChapuyRegaud*, M Jolivet † and G Serre* We developped an ELISA using a deiminated recombinant rat filaggrin (ArFA-ELISA) and assessed its diagnostic value for Rheumatoid Arthritis (RA). 714 sera from well characterised rheumatic patients, including 241 RA, were analysed. The results were compared to those obtained with another ELISA using a recombinant filaggrin of human origin and with those of two reference tests. Recombinant rat filaggrin was obtained by PCR amplification of Wistar rat genomic DNA, cloning, production in E. Coli and purification by metal chelate chromatography. The affinity-purified filaggrin was deiminated with type II rabbit skeletal muscle peptidylarginine deiminase. Deiminated and non-deiminated filaggrin were used as immunosorbents and the difference between optical densities on the two antigens were considered as the titer. The other tests were performed following previously described methods : 'AKA' were assayed by semiquantitative indirect immunofluorescence, antibodies to human epidermis filaggrin by immunoblotting (AhFA-IB) and by a recently described ELISA, using a deiminated recombinant human filaggrin (AhFA-ELISA). Whatever the chosen specificity threshold, the diagnostic sensitivity of ArFA-ELISA was significantly higher than that of the three other tests.
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Investigation of the epitopes of human profilaggrin derived peptide targeted by antibodies of patient with rheumatoid arthritis
The aim of this work was to study the presence of anti-skin antiintercellular (ASA-IC) and anti-basement membrane (ASA-BM) antibodies of the IgG class in patients with juvenile idiopathic arthritis (JIA) without clinical features of chronic vesicular-bullous diseases including pemphigus, pemphigoid and epidermolysis bullosa acquisita (EBA).
No D-penicillamine was used for JIA management in this group due to a risk of drug-induced pemphigus. Indirect immunofluorescence antibody test (IIF) and dual substrates of monkey and guinea pig esophagus sections were used for the detection and quantification of ASA-IC as well as ASA-BM antibodies. Overall ASA-IC were detected in 50 out of 57 studied patients´ sera samples (87,7 %, P = 0,0003) ranging from 1:20 to ≤ 1:320 dilutions. Respective of the classification criteria for idiopathic arthritis of childhood ASA-IC were observed in 6/6 patients with systemic disease (100%, P = 0,029), 24/29 patients with RF negative polyarthritis (82,7 %, P = 0,01), 16/18 RF positive polyarthritis (88,9 %, P = 0,0077) as well as in a small cohort of patients with oligoarthritis (2/2) and psoriatic arthritis (2/2). However we have observed a high incidence of antiskin anti-intercellular antibodies in a cohort of patients with JIA we suggest that subclinical pemphigus occuring in this group might be exacerbated with different stimulus including pemphigus inducing drugs. No ASA-BM antibody positivity was observed in a cohort of 57 studied patients. Autoantibodies to the nuclear antigen hnRNP-A2/RA33 are present in sera of RA patients and also in TNFa transgenic (tg) mice which develop severe erosive arthritis similar to human disease. Furthermore, autoreactive T cells have recently been found in peripheral blood of 60% of RA patients suggesting hnRNP-A2/RA33 to be also a major T cell autoantigen.
To investigate the pathway leading to loss of tolerance, expression of hnRNP-A2/RA33 was investigated by immunohistochemistry in synovial tissue derived from patients with RA and osteoarthritis (OA) as well as in joint sections of TNFa tg and control mice. These analyses revealed the antigen to be considerably overexpressed in RA as compared to OA tissue, particularly in macrophages of the lining layer and in fibroblasts of the sublining areas, whereas no or very little expression was observed in areas of lymphocyte infiltration. Remarkably, the antigen was not only located in the nucleus (as in cultured cells) but also abundantly detectable in the cytoplasm. Similar observations were made in TNFa tg animals in which strong hnRNP-A2/RA33 expression could be also observed at cartilage-pannus junctions. Interestingly, anti-A2/RA33 aab were not detectable in 8 animals treated with tissue inhibitor of metalloproteases 1 (TIMP 1) suggesting that metalloproteases may be involved in breakage of tolerance to hnRNP-A2/RA33. To elucidate the biological mechanisms leading to aberrant expression of hnRNP-A2/RA33 peripheral blood monocytes and T lymphocytes as well as cultured synovial fibroblasts and HeLa cells were treated with various stimulating agents including LPS, PHA, anti-CD3, IL-1, TNFa and IFNg or exposed to heat stress. However, none of these stimuli was able to induce upregulation or nucleocytoplasmic translocation of the antigen. Taken together, these findings suggest that the state of chronic inflammation in the rheumatoid synovium causes aberrant expression of hnRNP-A2/RA33 (and possibly other autoantigens). This may lead to increased uptake and (aberrant) degradation and presentation by macrophages and other antigen presenting cells subsequently activating autoreactive T cells which then may drive or enhance the inflammatory and destructive processes characteristic of RA.
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Autoantibodies to the mRNA destabilizing protein hnRNP-D/AUF1 in patients with systemic autoimmune diseases K Skriner, W Hueber, E Süleymanoglu, E Höfler, JS Smolen and G Steiner
Division of Rheumatology and Institute of Biochemistry, University of Vienna, 2nd Department of Medicine, Lainz Hospital, Vienna, Austria
The heterogeneus nuclear ribonucleoprotein (hnRNP) D, which is also known as AU-rich element binding factor 1 (AUF1), decreases stability of many short-lived mRNAs (including mRNAs of IL-1 and TNFa) by binding to adenosine and uridine rich sequences (ARE) contained in their 3´-untranslated regions. Previous studies had indicated this protein to be recognized by sera from patients RA, SLE and MCTD.
To investigate this autoimmune response in greater detail 356 sera from patients (pts) with various rheumatic disorders were tested by immunoblotting employing the recombinant 45 kDa variant of D/AUF1 (the largest of the 4 known D/AUF1 proteins). Autoantibodies (aab) were detected in 20% of RA pts (n = 105), 34% of SLE pts (n = 70), 17% of MCTD pts (n = 31) and in 25% of pts with primary Sjoegren´s syndrome (n = 21), but in less than 5% of 129 pts with other rheumatic disorders and not at all in healthy controls. Importantly, anti-D/AUF1 aab were already present in 25% of 60 patients with early RA of less than 6 months duration, whereas only one of 40 non-RA patients with other forms of early arthritis showed this antibody. Epitope mapping studies showed the aab to be directed to conformational epitopes in the N-terminal part of hnRNP-D/AUF1 known to be indispensable for the protein´s function. However, aab did not interfere with RNA binding as assessed by gel shift assays employing the ARE of the TNFa mRNA. Instead, they were able to supershift protein-RNA complexes indicating binding sites for RNA and aab to be distinct. Thus, these findings suggest that anti-D/AUF1 aab target the mRNA decay complex which may form another large ribonucleoprotein target structure in systemic autoimmunity. We are tempted to speculate that increased formation of such complexes (e.g. due to overexpression of instable mRNAs such as those for IL-1 and TNFa as seen in RA) may lead to pathologic autoimmune reactions against D/AUF1 and other proteins of mRNA decay complexes.
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The stress protein BiP is a major autoantigen in rheumatoid arthritis BiP (heavy chain binding protein) is the major chaperone of the endoplasmic reticulum that interacts transiently with most of the proteins of the secretory pathway and assists in their folding. BiP´s function under stress conditions is essential for cell viability and constitutively increasing or decreasing the BiP levels is detrimental to cell growth or to survival. Here, we present the RA autoantigen formerly designated "p68" as identical to BiP and that autoreactivity against BiP is a specific feature of RA. p68 was isolated and proven to be identical to BiP by two different approaches (Edman sequencing and MALDI-TOF mass spectrometry). Using tissue sections, BiP has been shown to be overexpressed in the RA as compared to the OA joint. Applying immunoblots, BiP-reactive autoantibodies were present in 63% of 400 RA patients, in 7% of 200 patients with other rheumatic diseases and in 1 of 150 healthy individuals. In patients with early arthritis approximately 50% are positive. An ELISA was established to quantify anti-BiP antibodies and the data of 400 RA and 400 control patients will be presented. The majority of RA sera was found reactive with a posttranlationally modified form of BiP and the major epitope was O-linked N-acetylglucosamine. Furthermore, we present evidence that BiP-specific T cell reactivity is pathogenically altered in RA. Overt BiP-specific T cell reactivity as determined by T cell proliferation assays could be observed in two thirds of patients with RA, but neither in healthy individuals nor in patients with other rheumatic diseases. Blocking anti-HLA-DR antibodies expectedly decreased T cell proliferation indicating the presence of HLA-DR restricted effector T cells. A subset of RA patients exhibited a BiP-specifically suppressed T cell reactivity. Blocking anti-HLA-DR antibodies in these assays Due to their different antiinflammatory and immunmodulatory effects corticosteroids are widely used in the treatment of SLE. Literature data support both Th1 and Th2 dominance in lupus. There are only few reports about cytokine profile of CD8+ T cells in SLE.
In the present study we examined by flow cytometry the cytoplasmic IFNγ, IL-4 and IL-10 expression in CD4+ and CD8+ T cells from six active, untreated, newly diagnosed SLE patients, who received after that 1 mg/kg methylprednisolon. Pretreatment expression of IFNγ was lower, while IL-4 and IL-10 expressions were higher in CD4+, but not in CD8+ T cells of patients than in control cells. Corticosteroid treatment increased IFNγ and decreased IL-4 and IL-10 expressions in patients' CD4+ cells, but had no significant effect on the cytoplasmic cytokine expression of CD8+ cells.
In conclusion, present results indicate that corticosteroid therapy does not influence INFγ, IL-4 and IL-10 expression in CD8+ T cells of lupus patients, and it may have pathogenic significance.
P16 Elevated IL-16 level is a non-genetic characteristic of patients with severe systemic lupus erythematosus LR Lard, BO Roep* and TWJ Huizinga
Departments of Rheumatology and Immunohaematology and Bloodbank*, Leiden University Medical Center, Leiden, The Netherlands
Introduction: IL-16, origanilly named lymphocyte chemoattractant factor, is a cytokine which is mainly produced by CD8+ T cells. Several reports have described that increased levels of IL-16 are in part responsible for T cell abnormalities in SLE patients. It is unknown if the previously reported increased levels of IL-16 is a characteristic underlying susceptibility to SLE or is a characteristic of the disease itself. Methods: Accumulated organ damage was measured with the SLICC/ACR Damage Index. Twenty-five severe (SLICC/ACR: 4.9 ± 2.5) and ten non-severe (SLICC/ACR: 1.0 ± 0.8) SLE patients were included in this study. Also 11 first degree relatives and 12 healthy volunteers were included in this study. Plasma IL-16 levels were measured by ELISA.
Results: No significant difference in the IL-16 levels of the first degree relatives of patients with SLE (38.3 ± 11.1 pg/ml) were observed when compared to controls (31.2 ± 10.1 pg/ml). In order to analyze characteristics of the SLE in relation to concentration of IL-16, IL-16 was measured in severe SLE patients (71.3 ± 87.4 pg/ml; P = 0.025) compared to healthy controls. On the other hand, no significant differences were observed between the non-severe SLE patients (37.8 ± 26.1 pg/ml) and controls.
Conclusion:
No evidence for increased IL-16 levels in first degree relatives of the SLE patients was observed. IL-16 is enhanced in SLE patients with a severe disease, but not in patients with nonsevere disease, thereby suggesting that IL-16 is associated with disease severity, and not with susceptibility for SLE.
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Functional and biologic evaluation of immunoregulatory cytokines in the immunopathologic lesion of Sjogren's syndrome DI Mitsias, AG Tzioufas, CI Veiopoulou, HM Moutsopoulos, G Thyphronitis
Department of Pathophysiology, Medical School, University of Athens
Autoimmune diseases are commonly considered to involve a Th1/Th2 imbalance in favor of Th1. Studies in mice suggest that the Th1 cytokines overexpression may be implicated in the pathogenesis of autoimmunity. Recent results, though, in humans challenge this notion.
Conflicting data have been published on the cytokine profile in patients with Sjogren's syndrome (S.s.). These data were mainly obtained using PCR based techniques and in-situ hybridization. Some of them indicate that a Th1 response is prevalent. To clarify this issue, small salivary glands (SGL) from patients with S.s. with different grades of infiltration as well as patients without S.s. but with sicca manifestations, were cultured in RPMI plus 40 IU/ml of recombinant IL2. IL4, IL13 and IFNgamma production in the culture supernatants (SN) was evaluated with a sensitive ELISA and, in parallel, mRNA levels for the same cytokines were evaluated with a quantative RT-PCR.
Within a period of a week, lymphocytes were evident in the cultures in numbers depending on the infiltration of the gland. The phenotype of these lymphocytes, as determined by flow cytometry, was similar to that published previously from SGL immunochemistry, suggesting that these cells derive from the salivary gland. SN were collected on various time intervals and mRNA was extracted from the lymphocytes on day 12 of the culture. Interestingly, IL13 mRNA was detected in almost all (17/19) of the samples, and both IFNgamma and IL4 on the majority (16/19 and 14/19, respectively). The cytokine production in the culture SN was examined in a set of 8 biopsies. IL 4 couldn't be detected ( <4 pg/ml), may be due to its binding on the IL4R. Both IFNgamma and IL13 were present and the ratio of IFNgamma/IL13 was related to the grade of infiltration (p <0.05), indicating that the balance of Th1 vs Th2 changes in favor of the former along with the severity of the disease. Finally, it was demonstrated that the Th2 cytokines IL4 and IL13 are functional since IgE was present in 12 out of 28 SN of cultured biopsies. IgE was present in greater quantities in those biopsies that had low grade infiltration (0-0.3 according to Chisholm's score) compared to those with medium grade (0.3-0.6), while in biopsies with infiltration >0.6 it was undetectable. These results show that in Sjogren's syndrome the distinction between Th1 and Th2 doesn't apply as both play a role to its pathogenesis. Moreover it seems that Th2 response prevails at the early stages whereas Th1 gradually augments as the disease progresses. Serum levels of IL-13 (pg/ml) were significantly increased in patients with RA (P < 0.00003), with SLE (P < 0.03), with SS (P < 0.0007), with ScS (P < 0.025) as compared to controls. IL-13 serum levels correlated with those of RF in RA (P < 0.00001), SLE (P < 0.003) and ScS (P < 0.03). IL-13 levels were higher in RA (P < 0.0002), SLE (P < 0.004) and ScS (P < 0.05) patients with RF than patients without RF. SS patients with anti-SSA/Ro antibodies had significantly higher IL-13 levels than SS patients without this autoantibody (P < 0.036). No statistically significative correlation was found between IL-13 levels and any other antinuclear autoantibody or total immunoglobulin levels or main clinical features of each disease. This study suggests that IL-13 may be involved in the pathogenesis of autoimmune rheumatic diseases, with a relevant role on RF production. In SS, the lack of correlation between IL-13 and RF is probably due to the peculiar characteristics of this antibody in the disease. We can conclude that the mechanisms involved in RF synthesis recognise different pathways depending on the underlying autoimmune disease. Leptin, the product of the ob gene, is synthesized exclusively by adipocytes to regulate the body weight in a central manner through its interaction with long isoform of leptin receptor ob-Rb. However, Ob-Rb is also expressed in lymphoid tissues and leptin has been shown to play an important role in cell-mediated immunity. We therefore decided to examine the role of leptin in vivo by analyzing the phenotype of mice deficient in leptin (ob/ob) or in ob-Rb (db/db) during antigen-induced arthritis (AIA). Arthritis was induced by an intraarticular injection of methylated bovine serum albumin (mBSA) in the knees of previously immunized ob/ob, db/db, control littermates and wild-type mice, all in C57BL/6 background. The severity of arthritis was determined by 99m Technetium (99m Tc) uptake. In addition, the degree of articular inflammation was also determined after sacrifice by histology scoring. Levels of circulating immunoglobulins and antibodies against mBSA were measured by ELISA. The responses of isolated lymph node cells to mBSA were also examined. The results showed that joint inflammation, as measured by 99m Tc uptake, was significantly reduced in ob/ob mice as compared with control littermates and wild-type mice (on day 1 of arthritis: P < 0.002 and P < 0.001, respectively; on day 3: P < 0.03 and P < 0.02, respectively). In addition, histology studies showed that ob/ob mice had markedly less synovial inflammation than lean controls (P < 0.04). In contrast, there was no difference in proteoglycan content within the articular cartilage as assessed by Safranin-O staining. The in vivo production of antibodies against mBSA was significantly decreased in ob/ob mice as compared with controls (P < 0.03). Circulating levels of IgG2a were also significantly lower in ob/ob mice than in controls, whereas levels of IgM were not different. In vitro lymph node cell proliferation in response to mBSA was significantly reduced in ob/ob mice as compared with controls. In addition, production of interferon-g by cultured lymph node cells was significantly lower in ob/ob than in control mice, whereas opposite results were observed for IL-10. Experiments performed in db/db mice confirmed the findings in leptin-deficient mice.
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In conclusion, leptin appears to regulate both the cellular and humoral components of the immune response against mBSA and to contribute to the mechanisms of joint inflammation in AIA. In addition, these results demonstrate that the effects of leptin on the immune system are mediated through its interaction with ob-Rb. Adjuvant-induced arthritis (AIA) in rats is a relevant model for human rheumatoid arthritis (RA). In this study, th expression of the cytokines TNF-alpha, IL-1 and IL-6, as well as the chemokines MIP-1-alpha, MCP-1 and ENA-78 in the sera and joint homogenates of AIA and control, sham-injected rats was studied over a 47-day period. All of these cytokines and chemokines showed increased production in AIA. In addition, TNF-alpha, IL-1, ENA-78 and MIP-1-alpha could be termed as "early" mediators, as their production increased in the first 14-21 days and it correlated with early events in synovitis, such as neutrophil ingress, joint swelling and general symptoms. TNF-alpha may have mostly systemic, while IL-1 mainly local synovial effects. IL-6 and MCP-1 were found to be "late" inflammatory mediators, as their secretion was up-regulated after 2 weeks post-adjuvant injection and remained high during the observation period. Also, significant correlation was found between the production of TNF-alpha and that of chemokines. In conclusion, the differential expression of "early" and "late" cytokines and chemokines may account for various events underlying synovitis in AIA. This study was performed to elucidate pathophysiological events prior and during the course of collagen-induced arthritis (CIA) in DA rats. Kinetic studies of local cytokine responses were determined using immunohistochemisrty and computer-aided image analysis. We also investigated the effect of the macrophage-pacifying compound CNI-1493 on proinflammatory cytokine expressions. Synovial cryosections were analysed at various time points for the presence of IL-1β, TNF and TGF-β. Unexpectedly, an early simultaneous TNF and IL-1β expression was detected in resident cells in the lining layer, preceding disease onset by more than one week. The predominant cytokine synthesis by synovial (ED-1+) macrophages coincided with clinical disease. TNF-production greatly exceeded that of IL-1β. CNI-1493 treatment did not affect the early TNF and IL-1β synthesis, while disease-associated TNF and IL-1β production was greatly reduced. Furthermore, CNI-1493 significantly up-regulated synthesis of the anti-inflammatory cytokine TGF-β and thereby shifted the balance of pro-inflammatory and anti-inflammatory cytokines in the arthritic joint in a beneficial way. Immune complexes can induce the production of various cytokines in vitro. Both IL-10 and IL-12 could be induced by addition of heataggregated immunoglobulins to mononuclear cells in serum-free cell culture systems. Addition of native serum to the cell cultures influenced the effects on IL-10 and IL-12 in opposite ways. While IL-10 levels were increased in cell cultures with native human serum, IL-12 production was inhibited as compared to cultures with monomeric IgG. Two series of experiments suggested that the effects of immune complexes on IL-12 production depended on the activity of the classical complement pathway in the serum: 1.) Heatinactivation of serum reverted the inhibitory effect of immune complexes on IL-12 production. 2.) C4 deficient serum behaved as a heat-inactivated normal serum concerning the effects on IL-12 production, and this effect could be reversed by addition of C4. The effects of neutralizing IL-12 had modest effect on immune complexinduced IL-10 production, and the effects of neutralizing IL-10 had no effect on IL-12 production. IL-10 production in the presence of immune complexes could be partially blocked by anti-FcgammaRII antibodies, while the immune complex-mediated effects on IL-12 not changed by blocking FcgammaRII or FcgammaRIII. Opposite and complement-dependent effects on the production of IL-10 and IL-12 can be of importance in cytokine-dependent autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus, where local or systemic activation of the classical complement pathway participate in the disease processes. Blocking of complement activation or receptors for activated complement components might gain increased attention as potential targets for immune therapies in the light of such cytokine-deviating effects. We have employed novel technology to investigate the relationship between synovial tissue oxygen levels and vascularity in human inflammatory arthritis. Silver microelectrodes were used to measure synovial tissue oxygen levels in knee joints of 15 patients with inflammatory arthritis (6 RA, 2 SLE, 1 psoriatic, 1 crystal, 2 reactive and 2 seronegative oligo-arthritides). Synovial membrane cells were obtained from tissue biopsies and ex-vivo production of vascular endothelial growth factor (VEGF) was measured. In RA patients, 50 ml N/Saline was injected into the joint and the electrode positioned in the cavity such that the rate of oxygen consumption could be measured. Microelectrodes were also used to assess synovial pO2 levels in a single metacarpophalngeal (MCP) joint in 5 RA patients. These joints were simultaneously imaged by high resolution ultrasound and power colour doppler to determine the relationship between joint architecture, vasculature and tissue pO2. In knees, synovial tissue pO2 levels were significantly lower in patients with active RA (mean = 7 mm Hg) than in patients without RA (mean = 40 mm Hg; P = 0.002). In RA, oxygen was consumed from N/Saline introduced into the cavity at a rate of 20.5 mm Hg/min. Production of VEGF from synovial cells was greater for patients with RA (mean = 868pg/106 cells) than from synovial cells from patients without RA (mean = 84pg/106 cells; P < 0.01).
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In the 5 MCP joints studied, a total of 9 vascular areas were sampled.
The mean pO2 at these sites was 97 mmHg. In 19 non-vascular areas sampled, the mean pO2 was 34 mm Hg (range 6-73). In a vascular erosion the tissue pO2 was measured as 41 mm Hg.
In conclusion, marked hypoxia is observed in selected regions of inflamed synovium and is a likely stimulus for local VEGF production and angiogenesis. However, the increased vascularity associated with erosive damage is insufficient to restore oxygen homeostasis at the site of joint destruction. Objective: Cartilage-derived morphogenetic protein-1 and -2 (CDMP-1 and -2) form a subgroup within the Bone morphogenetic protein family. While they are essential during embryonic joint and limb development, their role in postnatal articular cartilage is not fully clear. In this study we examined the stimulatory effects of CDMP-1 and -2 on proteoglycan synthesis and cell proliferation on postnatal human articular chondrocytes and investigated the hypothesis that osteoarthritic chondrocytes lose their responsivness to CDMP-1 and -2 compared to healthy cells and thus lead to a decrease in proteoglycan synthesis that impairs maintenance of matrix integrity. Methods: Chondrocytes were isolated from human articular cartilage from patients with and without osteoarthritic lesions. Cell number was assessed directly after collagenase digestion and chondrocytes were cultured as monolayers for a period of seven days in a chemically defined serum-free basal medium (BM) with and without the addition of recombinant CDMP-1 and -2. Introduction: IL-10 production differs between individuals. We have evaluated the IL-10 production in whole blood cultures with/without LPS. The comparison of monozygotic twins, sibs and unrelated individuals yielded an estimate of heritability of 70% (Lancet 98). Moreover the ex-vivo IL-10 production was associated with haplotypes defined by alleles of CA-repeats (PNAS 98). In line with these results we have demonstrated that the interindividual differences in production of mRNA encoding IL-10 are similar than the interindividual differences in IL-10 protein production (Rheumatology 2000). Aim: A) to define SNPs associated with common haplotypes. B) to study the association of IL-10 production with haplotypes/SNPs. C) to measure the distribution of IL-10 SNPs in RA versus controls. Methods: DNA of high and low IL10 producers were sequenced. Subsequently, the association between LPS-induced IL-10 production and previously described (Lancet 98) panel was analyzed. To investigate whether these SNP's were functional we analyzed the LPS-induced IL-10 production of 161 healthy donors with a specific genotype: -3575: AA (n = 38) 1896 ng/ml, AT (n = 76) 3232 ng/ml, TT (n = 47) 3195 ng/ml. -2849: AA (n = 21) 2115 ng/ml, AG (n = 75) 2950 ng/ml, GG (n = 65) 3111 ng/ml (Mann-Whitney test both P < 0.05). Next, the analysis was repeated in a different group of donors: 135 partners of patients with SLE/MS: -3575: AA (n = 29) 4190 ng/ml, AT (n = 71) 4521 ng/ml, TT (n = 35) 4401 ng/ml (MW-test P = 0.6).
P29
-2849: AA (n = 26) 3845 ng/ml, AG (n = 41) 4577 ng/ml, GG (n = 68) 4543 ng/ml (MW-test P = 0.04, for G carrier versus non G: P = 0.02). Next, the distribution of -2849 SNP was compared in RA patients compared to controls. Control-Panels were 1) partners of MS-SLE patients (n = 135) and 2) organ donors (n = 168). RApatients were: 1) incident RA cases, 2) outpatient consecutive RA and 3) RA patients from our early arthritis cohort.
Conclusion:
We (Eskdale et al, Lancet 98) have previously found that the allele IL-10R3 microsatellite was less frequent in three ethnic groups of RA patients (Afro-americans P < 0.01, English P < 0.008 and Scottish P < 0.02). The SNP that defines the haplotype on which R3 is located is also less prevalent in three groups of The molecular mechanisms that lead to lung fibrosis following lung inflammation in patients with scleroderma are unknown. The objective of this study was to identify patterns of abnormal gene expression in unfractionated bronchoalveolar lavage (BAL) cells from scleroderma patients. DNA microarrays were used to assess expression of over 4000 genes in BAL cells from 17 scleroderma patients and 7 controls. Hierarchical matrices were constructed and showed that BAL cell samples from patients with lung inflammation segregated into one cluster, whereas BAL cell samples from patients without lung inflammation and controls clustered in another. Next, 372 genes were identified that were expressed at least two-fold higher or lower in BAL samples from patients without lung inflammation, compared to controls. These genes, which may represent a scleroderma phenotype independent of tissue inflammation, clustered into eight groups. In rheumatoid arthritis (RA), the synovial fluid (SF) T lymphocytes present in the inflamed joints, display hyporesponsiveness upon engagement of the TCR/CD3 complex despite phenotypic evidence of former activation. We have previously shown that the central and crucial adaptor protein LAT (linker for activation of T cells), which plays a central and crucial role in the T cell receptor (TCR)-mediated signaling pathways, exhibits deficient phosphorylation due to displacement of the integral membrane protein from the plasma membrane in SF T lymphocytes. SF T lymphocytes exhibit several features of chronic oxidative stress, e.g. severely decreased intracellular levels of glutathione (GSH), and our previous studies have indicated that the subcellular localization of LAT is sensitive to changes in the intracellular GSH levels. The cysteine-to-serine substitutions of several cysteine residues (C26/29 or C117) within LAT creates LAT mutants that are resistant to reduced intracellular GSH levels and remain membrane-anchored in GSH-depleted cells.
In this study, we have used the redox-insensitive LAT mutants to study the effect of redox balance alterations, like in SF T lymphocytes, on TCR signaling pathways downstream from LAT and on CD28 signaling pathways. In co-transfection experiments, we show that the presence of the redox-insensitive LAT mutants allows for the partial restoration of the TCR-mediated signaling pathways, but not the signaling pathways induced through the CD28 receptor. The data are indicative that the Raf1-ERK and the calcium-calcineurin pathways leading to transcriptional activation of AP-1 and NFAT, respectively, are very sensitive to reduced intracellular GSH levels, while the activation of the p38/Mpk2 pathway leading to AP-1-mediated transcription is mostly unaffected by chronic oxidative stress. A very proximal event in the CD28-mediated signaling pathways seems to be extremely sensitive to GSH depletion since costimulation did not affect the transcriptional activity of either AP-1 or NF-kappaB. We conclude that the signaling pathways in SF T lymphocytes from RA patients are affected at several levels by chronic oxidative stress, all contributing to the observed hyporesponsiveness of these cells. Background: Rap1 is a small G-protein, member of the Ras GTPase family. Rap1 has been linked to T cell anergy and it is suggested that Rap1 has the potential to inhibit Ras-mediated oncogenic or growth promoting activity. Synovial fluid (SF) T cells from patients with rheumatoid arthritis (RA) display a defective phosphorylation pattern of several pivotal signaling proteins and severe hyporesponsiveness upon antigenic stimulation. Our previous data showed that the hyporesponsive state of the SF T cells in RA correlates with markers of oxidative stress and replenishment of the intracellular level of the anti-oxidant glutathione (GSH) by treatment with N-acetyl-L-cysteine (NAC) restores the observed signaling defects. Objective: To determine Rap1 activation and its correlation with oxidative stress in T cells from healthy controls compared to peripheral blood (PB) and SF T cells isolated from RA patients. Methods: T cells from healthy donors and PB and SF T cells from 5 RA patients were isolated and after 5 minutes of stimulation with either anti-CD3 antibodies or PMA+ionomycin, whole cell lysates were prepared in Ral lysis buffer. GTP-bound Rap1 was isolated using the bacterial expressed fusion protein GST-RalGDS and detected by ECL Western blotting. In whole cell lysates, total Rap1, rapGAP and Spa1 were detected by ECL western blotting as well. Results: Our data show that in T cells isolated from healthy controls, Rap1 was activated in a redox-dependent way. Upregulation of intracellular GSH levels by incubation with 10 mM NAC for 48 h resulted in diminished Rap1 activation, while depletion of GSH by pre-incubation for 48h with 200 µM BSO resulted in enhanced Rap1 activation. We also observed that treatment of T cells with H2O2 led to the rapid activation of Rap1. Despite an environment of oxidative stress in the inflamed joints of RA patients, we found that in SF T cells Rap1 was present in its inactive GDP-bound state. Furthermore, upon stimulation Rap1 remained inactive in SF T cells while in contrast Rap1 could be activated in PB T cells from RA patients. The defective Rap1 activation was not due to increased levels of the Rap1 GTPase activating proteins RapGAP or Spa1. While restoration of the intracellular redox balance does reverse the hyporesponsiveness of the SF T cells, the replenishment of GSH with NAC had no effect on the defective Rap1 activation. Conclusions: 1. In healthy T cells the small GTPase Rap1 is activated by H2O2; 2. Rap1 activation after T cell stimulation is redoxdependent; 3. Rap1 activation is defective in SF T cells from RA patients, and cannot be restored by the replenishment of GSH with NAC.
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The RIIbeta-subunit of protein kinase A (PKA) inhibits c-fos synthesis in T cells The aim of this study was to compare the invasive behaviour of FLS from RA and osteoarthritis (OA) patients and to investigate the effect of adenoviral (Ad) transfer of genes encoding IL-10 and TNFbinding protein (p55) (TNF-BP) on the invasive behaviour of FLS from RA patients. FLS from 43 RA and 28 OA patients obtained from synovial tissue harvested at joint replacement surgery, were seeded at confluency in serum free medium on top of a matrigel coated transwell filter with 8 µm pores. Medium with 10 % Fetal Calf Serum and 10 % Human Serum was used in the lower compartment. Three days post incubation cells were fixated, stained and the invaded synoviocytes on the lower side of the filter were counted. To test the effect of IL10 and TNF-BP, RA synoviocytes were infected overnight with 5, 10, 50 and 100 plaque forming units (pfu)/cell of Ad.IL10, Ad.TNF-BP or Ad.luciferase (negative control) and then tested in the invasion model. Significantly more RA synoviocytes invaded through the matrigel (median = 4035 cells) as compared to OA synoviocytes (median = 1900 cells; P < 0.001). IL10 and TNF-BP gene transfer both resulted in a dose dependent inhibition of invasion with a maximal inhibition of 93.7% (± 10.7) and 86.6% ( ± 14.5) respectively, while luciferase gene transfer showed a maximal inhibition of 17.6% (±1.7).
In conclusion, the invasive behaviour of FLS can be studied in the matrigel transwell system. This assay discriminates between the invasive behaviour of RA and OA FLS. The invasive behaviour of RA synoviocytes can be strongly inhibited by IL10 indicating that IL10 is able to downregulate the proteins involved in invasive growth. The inhibitive effect of TNF-BP indicates that continuous production of TNF is involved in invasive behaviour of synoviocytes. Mepacrine has been used for decades and the beneficial effects of this drug are well described. Since endothelial cells (EC) are in many cases the first cells to come in contact with drugs, the effect of mepacrine on certain aspects of EC biology were studied. First, our data demonstrate that at high doses mepacrine can have a marked impact on the integrity of the EC monolayer without grossly interfering with cell viability. The described impact of mepacrine on EC might explain, at least in part, the negative effects of this drug observed in the past. More importantly, mepacrine profoundly effects gene regulation in EC and fibroblasts. Mepacrine binds to DNA in a sequence specific manner. While NF-kB-DNA interactions are not effected, AP-1-DNA binding is blocked by mepacrine. Such differential effects are presumably due to sequence specific intercalation of mepacrine into the AP-1 consensus element. Pre-incubation of oligonucleotides resembling this sequence blocked the subsequent binding of nuclear extract containing AP-1 protein(s). Consequently, mepacrine prevents the upregulation of genes which depend mainly on the activation of AP-1. One of the few genes which have been found to depend heavily on the activation of this transcription factor is metalloproteinase-1 (MMP-1). We demonstrated by western blot that treatment of fibroblasts with mepacrine completely prevented subsequent upregulation of MMP-1. Since MMP-1 plays an important role in the propagation of rheumatic diseases, we suggest that the beneficial effect of mepacrine seen in the past is due, at least in part, to the described mechanisms.
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Patterns of differentially expressed genes in synovial tissue from RA and OA patients and from normal joints U Ungethüm, T Häupl, J Zacher*, A Gursche*, Förster † , P Reutermann ‡ , A Pruβ, V Krenn and G-R Burmester Objective: To identify key genes in the pathomechanism of rheumatoid arthritis (RA), synovial tissues from RA, osteoarthritis (OA) and from normal joints (ND) were compared by a subtractive hybridization technique, the representational difference analysis (RDA). Methods: Synovial tissues from 3 RA, 3 OA patients and 5 normal joints were selected according to their disease-characteristic immunhistochemical findings and to their expression of high versus low levels of inflammatory (IL-1β, TNF-α) and destructive markers (MMP-1, MMP-3) as determined by semiquantitative RT-PCR. Pooled mRNA from RA, OA and normal tissues was transcribed, digested by a 4-base-cutter, ligated to adapter-primers and amplified to form representational amplicons. Subtractive hybridizations were performed by different protocols: 1. the OA amplicon (driver) was subtracted from the RA representation (tester); 2. the RA (driver) from the ND (tester) and 3. the ND (driver) from the OA representaion (tester). Using primers specific for the corresponding tester, the difference-products were selectively amplified, cloned, sequenced and compared to published sequences in the Genebank. Differential expression of identified genes was validated by semiquantitative RT-PCR.
Results: Approximately 150 genes were found to be differentially expressed in RA synovial tissue as compared to OA or ND tissues respectively, or in OA tissues as compared to ND. Interestingly, some genes were identified to be overexpressed in both groups: RA (i.e. difference-product from RA minus OA) and OA (OA minus ND), indicating rather an association to general joint destruction than to RA-specific mechanism. Other genes were found to be differentially expressed only in the RA representation. 30 of the differentially expressed genes identified from each disease group were analyzed in synovial tissues from further 20 RA, 20 OA patient and 20 normal joints. The expression of some genes showed either a significant correlation to those of inflammatory genes (IL-1β and TNF-α) or to those of destructive markers (MMP-3).
Conclusions:
The analysis of differential gene expression in chronic joint diseases is a promising approach to identify deregulation of the inflammatory network to explain the inappropriate immune response with autoaggessive outcome. Furthermore a pattern of genes is generated which is specifically or preferentially expressed in RA. Such patterns will be of diagnostic value, especially for disease characterization, longitudinal studies and analysis of therapeutic effects. Rheumatoid arthritis (RA) is characterised by degradation of cartilage and invasion of fibroblast-like synoviocytes (FLS) into adjacent cartilage. Several families of proteinases are involved in the degradation of cartilage, especially the matrix metalloproteinases (MMP's) and cathepsin K. However, it is not known which MMP's are responsible for the degradation of cartilage and the invasiveness of FLS. In this study, the expression of MMP's 1 to 20 and cathepsin K in cultured FLS obtained from joint replacement surgery from RA, osteo-arthritis (OA) and other non-destructive arthropathies are investigated and compared to the invasiveness of the FLS in a matrigel transwell system. In this matrigel transwell system previous studies have shown that FLS from RA patients were significantly more invasive than FLS from patients with OA or other non-destructive arthropathies. FLS from synovial tissue of 32 RA, 18 OA and 14 patients with other non-destructive arthropathies were obtained from joint replacement surgery. The FLS were grown to confluency and RNA was isolated at passage 1 or 2. cDNA was synthesized using oligodT and reverse transcriptase. Expression of MMP's and cathepsin K was investigated using RT-PCR. For MMP's 2, 3, 7-12, 14-17, 19, 20 and cathepsin K RT-PCR was performed with primers for the MMP under investigation and primers for beta-actin in one mix. For MMP-1 and 13 no primers for beta-actin were in the mix. The intensity of the bands were compared and given a number from 0 (no expression) to 3 (intensity more than beta-actin). These numbers were related to the invasiveness (number of cells) in a matrigel transwell system. FLS that expressed MMP-1, MMP-3 or MMP-10 were significantly more invasive (median number of invasive cells: 3970, 4525, 4998, respectively) than cells that did not express MMP-1, MMP-3 or MMP-10 (1826, P = 0.02; 3081, P = 0.01; 2537, P = 0.01, respectively). Expression of the other MMP's and cathepsin K did not show a significant relationship with invasive growth. Expression of MMP-9 showed a trend with higher expression in more invasive cells (P = 0.09). From this study it can be concluded that a correlation exists between expression of MMP-1, MMP-3 and MMP-10 and invasiveness of FLS in a matrigel transwell system.
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The release of an ERK-activating factor from cartilage explants in response to trauma T Vincent, M Bolton and J Saklatvala
Kennedy Institute of Rheumatology, Aspenlea Road, London W6, UK
Mechanical injury to cartilage predisposes to premature degenerative arthritis but little is understood of the chondrocytic response to injury at the cellular and molecutar level. We have shown that the extracellular regulated kinase (ERK), the original mitogen activated protein (MAP) kinase, is strongly activated in porcine articular cartilage upon scarification in vivo, or following cutting of rested cartilage explants in vitro. Activation occurs within minutes and is sustained for 24-48h. It appears to be mediated by a soluble factor which is released into the culture medium by damaged cartilage. The factor is thermolabile and retained by dialysis membrane (10kDa cut-off). We have purified the factor through a series of chromatography steps (anion and cation exvhange, gel filtration and agarose-heparin columns), and are awaiting identification. It represents a potential homeostatic mechanism in response to injury, and could play a role in normal metabolism and degenerative arthritis. In patients with rheumatoid arthritis or juvenile idiopathic arthritis we observed the tendency of peripheral blood mononuclear cells to induce graft versus host disease like histhopathological changes of grade II or above (evaluated according to standard Lerner´s classification)when co-cultured in vitro with autologous skin explants. The aim of this study was to verify if observed skin damage was really of an autoimmune origin and we also tried to compare results with autoreactivity directed against autologous synovium. We suppose that humoral as well as cellular autodestructive mechanisms may be involved in the pathogenesis of observed skin damage. Methods:To prove this hypothesis (cellular autodestruction)we used 51Cr release cytotoxic test where peripheral blood mononuclear cells were co-cultured with autologous synovial cells as well as with autologous keratinocytes. Results: We found that patient´s peripheral blood mononuclear cells lysed both autologous keratinocytes (specific lysis 60%) as well as autologous synovial cells (59% specific lysis). No specific lysis of autologous keratinocytes and synovial cells was observed in healthy controls. We suppose that peripheral blood mononuclear cells might recognise similar autoantigen(s) expressed on epidermal cells that might give rise an autoimmune response in synovium.
P49 Enrichment of CD8+ CD28-cytotoxic T cells in circulating lymphocytes of patients with ankylosing spondylitis
M Schirmer, C Goldberger, C Duftner, J Clausen, A Falkenbach
Department of Internal Medicine, University of Innsbruck, and Gasteiner Heilstollen Hospital, Bad Gastein-Böckstein, Austria
Introduction: In patients with ankylosing spondylitis (AS), HLA-B27 restricted cytotoxic T lymphocytes (CTLs) exist with specificity for arthritogenic bacteria, viral peptides or autoantigens. These MHCclass I restricted CTLs could maintain the inflammatory process even after the bacterial pathogen itself had been eradicated by antibacterial immune responses and thus be directly involved in the pathogenesis of spondylarthropathies. Phenotypically they are characterized by CD28-negativity and CD57/CD11a high-positivity. This study was performed to directly compare the relative number of CD8+ CTLs from AS patients with age-matched healthy controls.
Until now only few data are available for the incidence of CD8+CD28-T cells in autoimmune diseases. Methods: AS patients were recruited and examined at the Gasteiner Heilstollen Hospital. Controls were preselected by evaluating the proband's history and physical examination excluding an inflammatory or autoimmune diseases. Peripheral blood mononuclear cells were isolated by Ficoll density gradient centrifugation, triple-stained for CD3, CD4, and CD28-antigens and analyzed on a FACScan flow cytometer. Results: Peripheral blood was analyzed from 95 AS patients and 53 age -matched healthy controls (49,1 +/-11,4 and 48.0 +/-14.0 years old, respectively). In AS patients CD8+CD28-T cells are expanded more than in the age-matched population (41,2 +/-17,7% and 18,6 +/-7,6% (P < 0,0001), with regression lines y = 0,23x + 29,85 (R2 = 0,02) and y = 0,03x + 17,03 (R2 = 0,004), respectively). The percentage of CD8+CD28-T cells does not increase over the decades in healthy controls. Trends are described for increased percentages of CD8+CD28-T cells in patients with severe disease. Conclusions: These data suggest that the fraction of CD8+CD28-T cells is not only increased in certain infectious diseases but also in patients diagnosed with AS. Increased percentages of CD8+CD28-T cells during ageing might be an artificial effect of undiagnosed infectious or autoimmune diseases. This finding further supports the hypothesis that increased levels of CD8+CD28-T cells can be considered pathogenic, comparable to benign monoclonal gammopathy. Nonspecific stimulation of the immune system by adjuvants can cause joint-specific inflammation in rats, as exemplified by arthritis induced with the endogenous cholesterol precursor squalene (C30H50). To determine the uptake and distribution of injected adjuvant, and more specifically to determine whether adjuvant accumulates in affected peripheral joints, tritium-labelled squalene was used to induce arthritis in arthritis-prone DA rats. All organs, including hind paws and the site of injection, were collected at different stages of disease development. The deposition of oil was subsequently quantified by dissolving the tissues followed by scintillation counting. The majority of injected oil never leaves the injection site, and no adjuvant oil is accumulated in the peripheral joints. Organ samples taken early prior to clinical disease and after arthritis onset displayed a similar distribution of oil, except for the draining lymph nodes and the intestines. In the draining lymph nodes, the deposition of oil accumulated over time, whereas the reverse was the case for the intestines.
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A passive transfer of squalene-induced arthritis with lymph node cells was successfully accomplished, both with cells from draining inguinal lymph nodes and cells from lymph nodes not draining the injection site (axillary). Since uptake of squalene was minimal in axillary lymph nodes, this result indicates that the oil need not be present for passive transfer of the disease.
In conclusion, we report an accumulation of the arthritis triggering squalene in the draining lymph nodes but not in the peripheral joints from the time of injection to the disease onset. This uptake evokes a systemic immune activation of unknown mechanisms that subsequently lead to a joint specific inflammation.
P52
p205 induces the production of rheumatoid factors F Schumann*, U Ungethüm*, S Adelt*, H Hofseß*, A Gursche † , J Zacher † , JB Natvig ‡ , J-M Engel § , G-R Burmester* and S Bläß* Sequencing and mass spectrometry by matrix assisted laser desorption-time of flight (MALDI-TOF) of p205 revealed that it containes sequences with similarity and identity to IgG and other members of the immunoglobulin superfamily. p205 was detected in the synovial membrane of RA patients by antisera specific for p205-derived peptides. Cells staining positive for p205 were also positive for the macrophage marker CD68. p205 staining did never occur in B cell clusters staining positive for CD19 or in T cell infiltrates staining positive for CD3. No B and T cells were detected in the highly p205-positive lining and sublining of the synovial membrane. p205 could react with monoclonal rheumatoid factors (RF). Those RF that reacted also with p205 tended to be of a binding specificity characteristic of RA. Those RF that did not react with p205 tended to be of a binding specificity that is also observed in healthy immunized donors or patients with Waldenström´s macroglobulominia. Synovial fluid (SF), SF-derived p205 and p205-derived peptides were used as antigens in T cell proliferation assays. As control antigens, a mock peptide and PHA were used. SF, p205 and p205-derived peptides stimulated T cells from two thirds of RA patients, but not from patients with other rheumatic diseases or from healthy individuals. SF, p205 and the 11aa p205 peptide with sequence identity to IgG were extremely high stimulators of proliferation in the majority of RA patients and were often in the range of the mitogen PHA. Two other p205-derived peptides were also stimulatory for RA-derived T cells, but to a lesser degree and at a lower frequency of patients. None of these peptides induced T cell proliferation in patients with other rheumatic diseases or healthy individuals. No reactivity was observed with the mock peptide in any of the patients. T cells specific for p205 cocultured in the presence of IgG-specific B cells induced the production of rheumatoid factors upon stimulation with cognate antigen and the 11mer peptide 3. RFs could also be induced upon immunization of rabbits with peptide 3. p205 is a major target of autoreactive T cells in RA and appears to be a novel member of the immunoglobulin superfamily. In an attempt elucidate the role of autoimmune processes in the pathogenesis of rheumatoid arthritis (RA) we investigated the T cell responses to two autoantigens targeted by autoantibodies of patients with RA, (i) the heterogeneous nuclear ribonucleoprotein (hnRNP) A2/RA33 and (ii) filaggrin which is one of the target structures recognized by anti-citrulline antibodies. Stimulation assays were performed with peripheral blood mononuclear cells of 50 RA patients, 20 patients with osteoarthritis and 21 healthy control individuals using recombinant hnRNP-A2/RA33 as well as some fragments thereof and recombinant filaggrin both in unmodified and citrullinated form. Antigen-specific T cell clones (TCC) were obtained by cultivating T cell lines in the presence of antigen and IL-2 followed by limiting-dilution cloning. Proliferative responses to hnRNP-A2/RA33 were seen in 60% of the RA patients with a mean stimulation index (SI) of 3.5±2.8 and were significantly higher than those observed in the control group (mean SI=1.7±1, P < 0.00005). There was no correlation with the presence of anti-A2/RA33 autoantibodies nor with MHC genes, although more than 60% of the responsive patients carried the shared epitope. Results obtained with recombinant fragments indicated a major T cell epitope to be located in the N-terminal first RNA binding domain of the protein. Anti-A2/RA33 specific TCC (n = 16) derived from RA patients were almost exclusively CD4+/CD8-, whereas only 7 of 12 TCC derived from controls showed this phenotype, and secreted high amounts of IFNg upon antigen stimulation as did all TCC derived from controls. Proliferative responses to filaggrin in either form were seen in only 25% of the RA patients tested and did not differ from those observed in the control group indicating that filaggrin-reactive T cells do presumably not drive the autoantibody response to citrullinated antigens. Taken together, a Th1 type autoimmune response to hnRNP-A2/RA33 was commonly observed in RA patients suggesting this nuclear protein to constitute a major T cell autoantigen which might be fuelling one of the pathological autoimmune reactions that drive the destructive processes effective in RA.
P55 Leflunomide leads to inhibition of transendothelial migration J Grisar, GH Stummvoll and JS Smolen
Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Austria
Leflunomide is a new disease modifying drug that is widely used in the therapy of rheumatoid arthritis (RA). The active metabolite of leflunomide A771726 leads to inhibition of dihydroorotate dehydrogenase, an enzyme necessary for pyrimidine de-novo synthesis.
Since activated lymphocytes expand their pyrimidine pool, A771726 leads to a decrease of their proliferation. A771726 also suppresses TNF mediated nuclear factor kappaB activation. We were therefore interested if A771726 also would be capable to influence transendothelial migration (TEM) of peripheral mononuclear cells (PBMC). We investigated the TEM of PBMC, which migrated through endothelial cell monolayers in an in-vitro model. Human umbilical vein endothelial cells (EC) were cultured to confluence on collagen gels and then incubated with human PBMC of healthy blood donors. PBMC were recollected in three groups: 1) cells that did not adhere to the endothelium, 2) cells that bound to the endothelium, 3) cells that had migrated through the endothelium, and then counted by microscope. Experiments in which PBMC as well as EC were treated with A771726 (in the absence or presence of uridine) were compared to simultaneously performed control experiments. No increased toxicity on the PBMC treated with the doses of A771726 used in our experiments, was observed. 24 hour incubation of PBMC and EC with 30 mg/ml A771726 led to a significant decrease in TEM (11±3 % vs. 6±3 % migrated cells, P = 0.016, paired T test NZB/W mice develop a disease similar to human systemic lupus erythematosus (SLE), including autoantibody production, hypergammaglobulinaemia and inflammation of the kidneys. It is known that large numbers of lymphocytes infiltrate the kidneys of these mice but the role of this organ for the production of antibodies is not clear. Here, we compare the role of bone marrow, spleen and inflamed kidneys of NZB/W mice for the activation of B cells and for the persistence of antibody secreting cells (ASC). ASC are present in the kidneys of mice with full blown disease, as many as in the spleen and bone marrow, and 50 times more than in the kidneys of normal mice. In the kidneys, ASC are located mainly in the outer medulla, close to B-and T cell infiltrates. The specificity of the ASC in the inflamed kidneys is not restricted to self-antigens. After immunization of NZB/W mice with Ovalbumin (OVA), the antigen-specific ASC are found initially exclusively in the spleen. Weeks later, during a period of at least 3 months, OVA-specific ASC are found in stable and high numbers within the bone marrow and the kidneys of these mice, but no longer in the spleen. As determined by FACS, B cells with a germinal center phenotype (B220+/PNA+) are found only in very low numbers in the kidneys, but in high numbers in the spleen of NZB/W mice. By histology, germinal centers could not be detected in the kidneys, but in the spleen. The lack of B cell activation and the kinetics of the appearance of OVA-specific ASC suggest that in autoimmune NZB/W mice kidneys, plasma cells generated during an immune reaction in secondary lymphoid organs, later accumulate and persist, like in bone marrow. These experiments identify the inflamed kidneys of NZB/W mice as site of prime relevance for the homeostasis of plasma cells, irrespective of their specificity, suggesting that chronically inflamed tissue attracts plasma cells as such and extends the overall capacity of the body for plasma cells, allowing autoreactive plasma cells to survive for long times within the inflamed tissue and to provide exorbitant titers of antibodies locally.
P58 In vivo preactivated autoreactive Th cells in healthy individuals
A Radbruch, S Nitsch, B Holzknecht, E Gromnica-Ihle, S Schneider, F Hiepe, A Thiel
Deutsches Rheuma-Forschungszentrum Cell Biology, Berlin, Germany
The direct analysis of autoantigen-specific Th-cells has been hampered so far by the lack of appropiate methods to directly determine their frequency or functional capabilities. We have applied a set of new techniques to directly identificate and analyze autoantigen-specific T-cells in both affected and healthy people according to their effector functions (e.g. effector cytokine production) after provocation with antigen. We have used these technologies to analyze Th-cells specific for SLE-associated autoantigens, in particular nucleosomes and the ribonucleoprotein La. Suprisingly, in vivo pre-activated autoantigenspecific Th-cells secreting IFNgamma and TNFalpha, could be detected not only in SLE-patients, but also in normal healthy persons, with frequencies ranging from 0.02% to 0.1%. Preactivation of these cells in vivo was confirmed by the fact that they expressed CD45RO but not CD45RA. Some of them had downregulated expression of CD45RB and CD27. We also detected in healthy donors in vivo preactivated Th-cell specific for the selfantigen alphaB-Cristallin, a small heat shock protein. Up to 0.5% of peripheral Th cells specifically react with IFNgamma secretion upon short term stimulation, a hallmark of a recall response, i.e. in vivo preactivation. The fact that in vivo pre-activated, autoantigen-specific Th-cells can be detected at comparable frequencies and with similar cytokine secretion patterns in blood of normal persons and patients suffering from a disease in which such Th cells are suspected to play a pivotal role, points to mechanisms other than central and peripheral tolerance that control the initiation of those autoimmune reactions. SLE is a systemic autoimmune disease with distinct immunological characteristics including defective T cell functions, especially concerning IL2 production and proliferation. Furthermore, B-cell hyperactivity is observed leading to the formation of several characteristic autoantibodies (ab), among them ab to the heterogenous nuclear ribonucleoprotein A2/B1 (hnRNP/RA33). These antibodies are known to occur in over 20% of SLE patients. In order to elucidate the role of T cells and their influence in antibody production in SLE, we studied proliferation of PBMC to purified hnRNP-A2/B1 in 34 SLE patients and 21healthy controls. While the stimulation indices (SI) in the healthy control group ranged from 0.5 to 3.5 (mean SI: 1.5 ± 0.9), the proliferative response of PBMC of the patient group ranged from 0.7 to 17 with a mean SI of 4.8± 4.0 (only 6 of 34 patients had an SI<2; P < 0.00004). We then proceeded to draw RA33-specific T cell clones (TCC) by cultivation and limiting-dilution cloning of T cell lines. The generated 30 TCC derived from SLE patients and 19 TCC from healthy controls did not reveal a significant difference in SI and produced either more IFNγ than IL4 or none of these cytokines at all, suggesting that these TCC were of T1 or T0, but not T2 phenotype. Interestingly though, while only 11% of healthy control patients showed a CD4-/CD8+ subtype and 16% displayed a CD4+/CD8+ phenotype, 37% of TCC derived from SLE patients were CD4-/CD8+ (and 20 % expressed CD4 as well as CD8). Our data reveal that more than 80 % of SLE-patients have a significant T cell reactivity (SI ≥ 2) to the nuclear protein hnRNP-A2/B1 indicating that the antibody response might be T cell driven. Furthermore, almost 60% of TCC derived from SLE patients were CD8+, which supports the importance of these T cells in SLE. Further studies will have to elucidate the pathogenetic implications of these findings. Aim: Dominating defects in SLE are demonstrated in humoral immune response, however, various T cell defects were observed. Recently, some authors referred to about the abnormalities in signalling after TCR activation and about CD3ζ chain deficiency of some SLE patients (1,2,3) . The reports differed in many details and, therefore, we decided systematically to test these results and to study molecular architecture of such signalling complex. Methods: Isolated periferal blood lymphocytes (PBL) from SLE patients and controls were analyzed for the presence of CD3ζ chain using immunoblot assay with mouse monoclonal anti-CD3ζ chain antibody and secondary antibody conjugated with peroxidase followed by chemiluminiscence. Lysis of PBL was performed either following the method of American authors (1, 2) or by the method used in the laboratories studying the molecular aspects of TCR signalization (e.g. Dr. V. Hoøejší, Prague). T cell signallization was stimulated by cross-linking TCR with monoclonal antibody against CD3ζ (MEM-92) and tyrosine phosphorylated proteins were detected using monoclonal antibodies (P-TYR1 and P-TYR2) by immunoblotting. Results: The defect of CD3ζ chain was found in 17 of 45 SLE patients (38 %) using the protocols published by American group and was never found in 15 controls (healthy or not SLE patients). But, we could not find this defect using the improved protocol in 59 SLE patients, including all of the previous group. Signalling was different in patients compared to controls in that unstimulated cells from patients showed the pattern observed in stimulated controls but the results were dependent on the conditions by which PBL were brought to the so-called "inactive" or quiet state. Conclusion: Conflicting results show that the published CD3ζ chain deficiency in SLE patients could be caused by the methodical approach. Defect in signalization must be defined more precisely under strictly controlled conditions. Here, we will show that under certain conditions human peripheral blood (PB) TC, once activated by anti-CD3 monoclonal antibody (mab) in vitro, fail to respond to a subsequent re-stimulation via the TCR. This unresponsiveness is caused at the transcriptional level by an impaired production of IL-2, and this defect is temporary. Methods: PB mononuclear cells (MC) from healthy donors were pre-stimulated (PS) by anti-CD3PS for 96 h following restimulation by IOT-3, IL-2, or IL-15, as well as other mitogens. In control experiments (NS), PBMC were cultered in medium alone for the first 4 days. Restimulation of both populations was also performed in the presence of freshly isolated monocytes (MO). Furthermore, after the first incubation T-cells and MO from PS and NS cultures were seperated by magnetic beads and incubated for re-stimulation in a criss-cross design. Surface immunophenotype of both, TC and MO were analysed by flow cytometry. Cytokine production was determined by rtPCR and intracellular signaling protein content of TC in PS and NS cultures were compared by western blotting. passage seeded on collagen gels and incubated over night. PBMC were prepared from 6 patients (5f, 1m, mean age 55±6.5 yr.) fulfilling the ACR criteria for SSc and 6 healthy controls (HC; 5f, 1m, mean age 55±7.11 yr.). Lymphocyte-migration was measured after one hour of incubation by fractionated harvest of non-adherent, bound, and migrated lymphocytes. Changes in the CD4/CD8 ratio and in the lymphocytic expression of activation markers (CD25, HLA-DR, CD69) and adhesion molecules (CD11a, CD49d) ex vivo, during and after migration were investigated by fluorocytometry.
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Results:
The percentage of migrated SSc lymphocytes was increased in each single experiment (Fisher´s exact test P < 0.03) when compared to HC (9.0±4.4% vs 5.3±2.9%). Compared to HC, the CD4/CD8 ratio was only slightly higher in SSc when detected ex vivo (2.71±0.76 vs. 2.22±0.54, P = n.s.), but increased after migration (3.00±0.57 vs. 1.01±0.38, P < 0.02), whereas the CD4/CD8 ratio in HC fell. The expression of lymphocytic activation markers and adhesion molecules was similar in SSc and HC ex vivo. Migrated SSc lymphocytes tended to express higher amounts of CD 25 and CD 49d, but this did not reach statistical significance in our small sample of patients. Discussion: Lymphocyte migration through a human endothelial monolayer is increased in SSc and is accompanied by an increase of the CD4/CD8 ratio. These data suggest that CD4+ SSc cells are more prone to migration than CD8+ cells and are in line with the paravascular accumulation of CD4+ lymphocytes. Results: In the synovial lining CD68, CD163 and HLA-DR were increased in SpA versus RA; in the sublining CD163 and HLA-DR were also increased. In contrast, costimulatory molecules and dendritic cell markers were scarce in SpA versus RA synovium. Interestingly, CD 163 and CD68 were also increased in colonic lamina propria in SpA. CD163 and HLA-DR in the sublining were correlated with CRP and ESR. CD163+ macrophages expressed high levels of HLA-DR and could produce TNF-alpha but not IL-10. Anti-TNF-alpha therapy in SpA induced a decrease of CD163 in both synovial lining and sublining. Conclusions: Macrophages expressing the scavenger receptor CD163 are increased in synovium and colonic mucosa in SpA, highlighting the relation between joint and gut. The correlation with inflammatory parameters, the expression of HLA-DR, the production of TNF-alpha but not IL-10 and the reduction by anti-TNF-alpha therapy support a role for CD163+ macrophages in synovial inflammation in SpA. Distinct myeloid DC and lymphoid DC subsets have been described, which regulate the nature and magnitude of immune responses. Therefore DC function must be carefully regulated, otherwise inappropriate responses may result in such chronic inflammatory diseases as rheumatoid arthritis (RA). In this study the composition and activation state of DC subsets was compared between autologous blood, synovial fluid and synovial tissue of RA patients using 4-colour flow cytometry. Preliminary results indicated that RA blood and normal blood had a similar ratio of DC subsets, both of which exist in a relatively inactivated state. In contrast, myeloid DC were predominant in RA synovial fluid and synovial tissue. In synovial tissue these myeloid DC were more highly activated and localized to lymphoid aggregates. Lymphoid DC were scarce in both synovial fluid and synovial tissue.
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P66 Fully competent dendritic cells as inducers of T cell anergy in autoimmunity S Quaratino, LP Duddy and M Londei
Conclusion:
These results suggest that myeloid DC play a key role in the pathogenesis of RA and supports the view that RA is predominantly a Th1-mediated disease.
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Detection of bacterial components in synovial tissue from patients with inflammatory arthritis by using PCR with pan bacterial 23S rRNA and 16S rRNA primers, and gas chromatography-mass spectrometry T Chen*, M Rimpiläinen*, R Luukkainen † , T Möttönen ‡ , T Yli-Jama § , J Jalava* and P Toivanen* 
Clinical Immunology Unit and Chair, Spedali Civili and University of Brescia; Division of Medicine, Niguarda Hospital, Milan, Italy
Background: the determination of the fine specificity of antiRo/SSA response is useful in the classification of the risk for the occurrence of congenital complete heart block (CCHB) in newborn of anti-Ro/SSA mothers. Aim of the study: to evaluate different methods for the detection of anti-52 and 60 kD Ro/SSA antibodies. Patients and methods: 132 sera (82 from anti-Ro/SSA patients by counterimmunoelectrophoresis (CIE), 30 from anti-ENA positive/ anti-Ro/SSA negative and 20 from ANA and anti-ENA negative) were tested by ELISA with recombinant 52 and 60 kD Ro protein (Pharmacia Upjohn, Germany) and immunoblotting (IB) with human spleen extract (HSE) as substrate to the aim of determining the fine specificity of anti-Ro response. In addition, 21 sera from mothers of CCHB children were tested by CIE, two ELISAs with recombinant proteins (Pharmacia and Euro-diagnostica, The Netherlands), two IBs with HSE and with HEp-2 extract as substrates (MarDx, USA). Results: the total agreement between ELISA (Pharmacia) and IB (HSE) was 76% for anti-Ro 60 kD and 44% for anti-Ro 52 kD. The ELISA was more sensitive than IB both for anti-Ro 60 kD (91% vs 84%) and for anti-Ro 52 kD detection (82% vs 51%). Seven sera positive by CIE were negative by IB (non blotters): six of these sera were positive for anti-60 kD and 2 for anti-52 kD by ELISA. The mean antibody titre for anti-60 kD was significantly lower (P < 0.00005) than that of sera detected by IB. A correlation ranging from 78 to 100% was detected between the different methods testing the sera from CCHB mothers. The agreement between the IB methods for anti-Ro 60 kD and for anti-52 kD was 79% and 68.5% respectively while between the ELISAs was 44% and 67% respectively. The best agreement obtained comparing IB and ELISA for anti-Ro 60 and 52 kD was 78% between IB with HSE and ELISA (Euro-diagnostica). Conclusions: ELISA seems to be the most sensitive method to detect the fine specificity of anti-Ro/SSA response. The majority of IB negative/CIE positive sera (non blotters) were positive for anti-60 kD by ELISA at low titer. IB with HSE as substrate performed slightly better (p not significant) than IB with HEp-2 cells extract in CCHB mothers. antibodies. Anti-pep349-364 antibodies, purified from different patient sera were all found to recognize the same anti-cpep F(ab´)2 suggesting that a common idiotype exists. Immunizations of BALB-c non-autoimmune mice with pep289-308 produced anti-pep289-308 followed by the production of anti-cpep289-308 antibodies 10 days later. In a similar manner immunization with cpep289-308 led to the appearance of anti-cpep289-308 followed by the formation of anti-pep289-308 antibodies. In conclusion, antibodies to B-cell epitopes of La/SSB contain in their antigen binding site a common idiotype which can be detected using complementary peptides to these epitopes. Antibodies to La/SSB epitopes are target of an antiidiotypic response against this common idiotype. Manipulation of this Id -anti-Id network may provide potential insights into the understanding of the molecular mechanisms for autoantibody production and therapeutic approaches. cell epitopes which is recognized by sera from patients with primary Sjogren's Syndrome (pSS) and by different predictive methods share also putative T cell epitope properties. The 289-308 epitope (denoted Po25) and its complemetary form encoded by complementary RNA (denoted Pcpl25) were conjugated on Sequential Oligopeptide Carrier (SOCn). SOCn is formed by the (Lys-AibGly)n sequential motif, where n = 2-7, and the peptide antigens were anchored to the lysine groups so as they retain their original structure and they obtain favorable molecular recognition conformations. Different doses of peptide carrier formulations were administrated alone or together with Freud's adjuvant (CFA/IFC) and specific antibody and lymphoproliferative response were determined. Both the in vivo and in vitro responses were dose dependent and a demonstrable cross reactivity was observed at the T and the B cell level. Immunization with Po25-SOC resulted to the induction of anti-Pcpl25-antibodies and immunization with Pcpl25 led to the production of anti-Po25 response indicating the regulatory activity of anti-idiotypic antibodies. On the other hand immunized mice also primed specific T cell proliferative responses in spleen. The ability of complementary peptides to prime both anti-idiotypic and T lymhocyte responses may be central to their potent immunization properties in regulating autoreactive B and T cells. With this approach we aim to shed light to the immunoregulatory mechanism(s) which underline the autoimmune response.
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P73 Structure and function of an autoantigen, alphaenloase S Moscato, F Bongiorni, F Pratesi, M Scavuzzo, S Bombardieri and P Migliorini
Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
The glycolytic enzyme 2-phosphoglyceratelyase (alpha-enolase) is an autoantigen in connective tissue disorders, and more frequently in patients with active renal disease. The enzyme has pleiotropic functions: it is also a structural protein, a stress protein induced by hypoxia and it acts as transcription factor in the nucleus. Alpha enolase is encoded by a single copy gene and only one mRNA species is detected. In order to define a structural basis for these different functions, we analyzed the isoelectric point of the enzyme. On a kidney extract fractionated by 2D electrophoresis, a mouse antienolase antiserum detects 5 spots of identical molecular weight but differing in pI. Some autoimmune sera react with all the spots, while other recognize only the acidic forms of alpha-enolase. We then analyzed the properties of the membrane form of enolase. Enolase is not a membrane structural protein, but it is strongly associated with the membrane, where it acts as plasminogen receptor. Anti-enolase antibodies purified from autoimmune sera react also with the membrane form of alpha-enolase: by flow cytometry, 7/9 antibody preparations bind in fact U937 cells, a human lymphomonocytoid cell line that expresses high density of plasminogen receptors. To investigate the possible functional role of membrane enolase, we evaluated the ability of monoclonal anti-enolase antibodies to induce cell damage or apoptosis. No monoclonal had a cytotoxic effect on U937 cells or was able to induce apoptosis in the same cell line. We then tested the ability of monoclonal anti-enolase antibodies to induce Ca2+ influx in U937 cells. One out of 4 monoclonal antibodies induced release of Ca2+ from intracellular stores.
In conclusion, alpha-enolase exists as multiple isoforms, probably due to postranslational modifications, which seem to affect recognition by autoantibodies. It is presently unknown whether these modifications are tissue-specific and/or affect membrane expression of the enzyme. A possible link between Ca2+ influx and receptor functions of enolase is currently under investigation. 
Introduction:
The ribosomal phosphoproteins P0, P1 and P2 are targeted by autoantibodies in SLE. The presence in the patient sera of the anti-P antibodies is highly specific for the disease and correlates with psychiatric, renal and liver involvement. In order to better characterize these autoantibodies (reactivity, specificity and epitope recognition), recombinant anti-P monoclonal antibodies were isolated from an human SLE patient derived phage display library. Methods: Two synthetic peptides were used to select the recombinant anti-P antibody fragments: a synthetic peptide representing the C-22 common immunogenic region of the three P proteins and the multiple antigenic peptide (MAP) carrying four copies of the last 13 residues of the C-22. The human library was derived from the bone marrow lymphocytes of an anti-P positive SLE patient. The selected anti-P antibodies were tested for reactivity with the C-22, the MAP and a control panel of recombinant autoantigens in an ELISA assay. Specificity of the selected antibodies was further analyzed by immunoblotting and immunoprecipitation assays using Jurkat total cell extract. Indirect immunofluorescence staining on HEp-2 cells was also performed. Using different synthetic peptides derived from the C-22 peptide epitope recognition was further characterized in an ELISA assay. Sequencing of the selected antibody fragments was performed and the antibody sequence was compared to the nearest germ-line sequence. In all the experiments human anti-P positive control sera were included. Results: Six recombinant anti-P antibodies were isolated from the human library when using the C-22 synthetic peptide. Some of the isolated antibodies reacted specifically with the C-22 antigen in ELISA, others recognized the ribosomal P proteins on Western blot, immunoprecipitated the P proteins from the Jurkat cell extract and showed cytoplasmic staining on HEp-2 cells in an immunofluorescence assay. The selected antibodies exhibited features similar to serum antibodies of the patients with respect to their reactivity, specificity and epitope recognition.
Conclusions:
The phage display technology proofs once again to be a very useful technique for the production of human monoclonal autoantibodies and for the characterization of the reactivity and specificity of these autoantibodies. Anti-histone and anti-chromatin antibody responses play a central role in the autoimmune response of systemic lupus erythematosus (SLE). Furthermore, anti-histone H1 antibodies are essential for the formation of the lupus erythematosus cell (LEC) phenomenon. In this study, the binding properties of LEC+ and LEC-SLE sera to chromatin-associated nuclear antigens (histones H1, H2A, H2B, H3, H4; complexes of H2A-H2B, [H2A-H2B]-DNA, H1-DNA; total and H1-stripped chromatin; native and denatured DNA) were investigated. In addition, sera from patients with drug-induced lupus (by procainamide, hydralazine, or quinidine), as well as from patients with rheumatoid arthritis and osteoarthritis, were assessed. Enzyme-linked immunosorbent assay was used to detect specific antibody binding. Mirroring the important role of histone H1 in the formation of LE cells, anti-histone H1 reactivity was 8-fold higher in LEC+ sera than in LEC-sera. In addition, reactivities to most of the other antigens tested, i.e., other histones and histone-DNA complexes as well as chromatin and DNA, were significantly higher in LEC+ sera than in LEC-sera. All but 1 serum sample from the patients with drug-induced lupus were negative for LE cell formation as well as for anti-histone H1 reactivity, but displayed high antibody reactivities to histone-DNA complexes, including chromatin. Sera from patients with rheumatoid arthritis and osteoarthritis did not show significant binding to these antigens. When comparing the clinical features of LEC+ and LEC-SLE patients, severe organ involvement, including nephritis and central nervous system involvement, was common in the LEC+ group, but rare in the LEC-group. A positive LE cell phenomenon not only correlated with the presence of high anti-histone H1 antibody levels in SLE, but also indicated serologically and clinically active disease with major organ involvement. pts. 30 patients were tested for anti-SM, anti-U1RNP, cANCA and pANCA and were positive in: anti-SM-20.0%, anti-U1RNP-50.0%, cANCA-10.0%, pANCA-30.0%. Results: there was no statistically significant correlation between ANA, anti-dsDNA, CIK, anti-DNP, C3/C4 and the diagnosis of certain neuro-psychiatric manifestations in our SLE patient group. Patients with focal cerebral dysfunctions were shown to have a higher frequency of aPL: LA (P = 0.0111) and aCL (P = 0.0148). A correlation was found between cANCA (P = 0.0406), pANCA (P = 0.0348), anti-U1RNP (P = 0.0309) and skin vasculitis, as well as between pANCA and CVI diagnosis in neuro-lupus patients (P = 0.0028). Conclusion: our study did not show the correlation between autoantibodies in SLE patients with NP and certain types of CNS/PNS lesions, except for the connection between aPL and focal cerebral dysfunctions, as well as pANCA's correlation with cerebro-vascular stroke diagnosis.
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The The antiphospholipid syndrome is characterized by a wide variety of vaso-occlusive manifestations associated with autoantibodies directed against β2-glycoprotein-I. The pathogenicity of anti-β2GPI antibodies has been demonstrated in animal models. The factor(s) causing production of anti-β2GPI remain unidentified, but several indirect arguments support the idea that microbial agents might influence the course of antiphospholipid syndrome and an association with microbial pathogens has recently been documented. Microbes can contain chemical structures that mimic normal host self-proteins, a phenomenon termed molecular mimicry. Employing a peptide phage display library, we identified hexapeptides that react specifically with anti-β2GPI monoclonal antibodies. These peptides were found to modulate the experimental model for antiphospholipid syndrome. In the current study we found high homology between one of the hexapeptides-TLRVYK, and various bacteria and viruses. We therefore immunized naive mice with a panel of TLRVYK-corresponding microbial particles to find whether they posses a pathogenic potential for autoimmunity. We show that mice which were infused with antibodies derived from mice immunized with tetanus toxoid, haemophilus influenzae or with neisseria gonorrhoeae developed clinical manifestations of experimental antiphospholipid syndrome (e.g. mice infused with anti-β2GPI derived from tetanus immunized developed thrombocytopenia 497±98X10 -3 cells/dl compared to 1012±214x10 -3 cells/dl in control mice, high percentage of fetal resorption 48±3% in comparison to 4±2% and prolonged aPTT 69±4sec in comparison to 23±3sec in mice infused with IgG from Shigella disenteriae immunized mice). The pathogenetic mechanism for anti-β2GI generation seems to be an epitope mimicry with common bacterial molecules. antibodies. These antibodies are of considerable clinical importance because of their strong association with thrombosis, recurrent fetal loss, and thrombocytopenia. Although β2GPI has been shown to have a number of anticoagulant properties in vitro, its role in vivo is unknown. The aim of this study was to evaluate the function of β2GPI in vivo using a β2GPI deficient mouse model. We employed homologous recombination to disrupt the β2GPI gene in embryonic stem cells, which led to the generation of mice deficient in β2GPI.
P79 Impaired in vitro thrombin generation in
To confirm that the appropriate gene was targeted, nucleotide sequencing, map location, Northern blot analysis and Western blot analysis of the expected protein was performed. Following heterozygous (+/-) intercrosses, a total of 336 surviving offspring were genotyped. Interestingly, only 8.9% of these offspring were homozygous (-/-) for the disrupted allele, suggesting an effect on embryonic implantation or development. The remaining β2GPI-/-mice progressed normally to term and the adult mice appeared to be normal by anatomical and histological analysis. However, in vitro thrombin generation using a novel chromogenic assay demonstrated that there was a marked decrease in thrombin generation in -/-(OD405=0.175) compared to +/-(OD405=0.312) and +/+ (OD405=0.576) (n = 10). This would indicate that β2GPI is likely to have a prothrombotic role in vivo. This finding is in contrast to results obtained in in vitro assay system using purified β2GPI which demonstrate anticoagulant activity for β2GPI . These knockout mice also provide a valuable in vivo model system for exploring the role of β2GPI in disease pathogenesis. There are still considerable interlaboratory differences in positivity rate in anti-β 2 GPI ELISA. We have already shown that BSA as a blocking agent could introduce a substantial interference effect in an anti-β 2 GPI ELISA. The aim of this study was to validate and possibly reduce an interference effect of different blocking agents on the detection of IgG anti-β 2 GPI antibodies by ELISA. We used Costar high binding plates coated with affinity purified human β 2 GPI and blocked with 1% BSA or 3% gelatin in PBS. Selected sera (20 NHS, 20 APS sera and 10 sera from children with atopic diseases) were diluted in PBS containing 0.05% Tween (PBS-T) or in 0.1% BSA/PBS-T or in 1% gelatin/PBS-T. When plates were blocked with BSA and samples diluted in PBS-T, 11/50 sera expressed values above the cut-off level in the wells coated with β 2 GPI and also substantial binding in sample blanks wells (SB) mostly exceeding the binding to the antigen, therefore these samples were considered negative (average SB for all sera = x±SD=63±127 mOD). The specificity of IgG antibodies yielding high background bindings was confirmed by direct binding to BSA on solid phase (correlation with SB: P < 0.001, R 2 =0.88) and efficient inhibition by fluid phase BSA. Further, the sera were diluted in 0.1% BSA/PBS-T, which resulted in negligible binding to BSA either directly coated on the plates or used as the blocking agent and hence lowered SB to insignificant levels (SB=13±9 mOD). Following this modification, 3/11 sera previously found negative due to high SB values, clearly expressed low positive IgG anti-β 2 GPI values. The inhibition of anti-BSA with 0.1% BSA in fluid phase was almost complete in 3 minutes, suggesting that longer preincubation time may be unnecessary. 1% gelatin/PBS-T as the sample diluent buffer did not prevent the substantial binding to BSA used as the blocking agent either (SB for 20 sera with the highest binding to BSA =203±262 mOD). The same was true even when the plates were blocked with 3% gelatin and samples diluted either in PBS-T (SB=117±120 mOD) or in 0.1% BSA/PBS-T (SB=127±122 mOD) generating substantial SB values in 18/38 tested sera. Similarly to BSA, significantly lower background bindings were reached only when gelatin was used as the blocking agent and 1% gelatin added to the sample diluent buffer (SB=30±21 mOD).
To reduce the interference effects of a blocking agent it was essential to dilute sera in a buffer containing the same agent. Since the binding to BSA or gelatin was detected in both normal human and patients' sera we suggest to follow this general guideline in anti-β 2 GPI ELISA to better define the cut-off points and to more accurately verify not only high, but also most of low positive results.
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Heterogeneous behaviour of anti-β β 2 -glycoprotein I antibodies on different "high binding" microtiter plates We recently identified anti-β 2 GPI antibodies in a high proportion of sera from children with atopic dermatitis (AD) and showed that these anti-β 2 GPI most probably recognise domain V of β 2 GPI by contrast to anti-β 2 GPI from patients with the anti-phospholipid syndrome (APS) which epitopes apparently reside in domain I or IV. The aim of the present study was to compare the binding of IgG anti-β 2 GPI in AD and APS on four representative commercially available types of high binding microtiter plates. Selected plates: Costar, Nunc, Linbro and Sumilon C. Randomly selected sera from 29 children with AD and sera from 43 SLE patients (24 with secondary APS) were tested by anti-β 2 GPI ELISA using affinity purified β 2 GPI. Assays were calibrated with the HCAL, chimeric anti-β 2 GPI monoclonal antibodies with human γ1 constant regions.
The calibration curves for HCAL were practically the same on all four types of plates. Sera from 7/24 APS patients with medium or high anti-β 2 GPI levels showed similar binding properties on all four plates, while 3/24 sera expressed values either slightly above or below the cut-off points. On the other hand, anti-β 2 GPI from AD sera showed very simmilar binding on Costar, Nunc and Linbro plates, while only 3/13 positive sera with the highest values on these 3 types of plates expressed low positive values for IgG anti-β 2 GPI on Sumilon C plates (Table 1) . Except for one serum (low positive on Linbro plate) all sera from SLE patients without APS were negative on all the plates. Our results point to substantial differences in the binding to β 2 GPI coated on different microtiter plates by anti-β 2 GPI in AD (with no signs of APS) but not by anti-β 2 GPI in APS. In contrast to the other plate types, Sumilon C plates coated with β 2 GPI bound only minimally antibodies from AD children. If such anti-β 2 GPI prove nonthrombogenic, we will be able to increase the specificity of detecting anti-β 2 GPI relevant for APS by the use of this type of microtiter plates. Alternatively, if both anti-β 2 GPI specificities prove thrombogenic, we will be able to increase the sensitivity of the assay system by the use of other less discriminatory types of plates. We investigated whether β 2 GPI, the key antigen in the antiphospholipid syndrome, is susceptible to oxidative modifications by the hydroxyl radical (°OH) that may influence its lipid-binding and antigenic properties. We compared the effects on human and bovine β 2 GPI of °OH free radicals generated by γ-radiolysis of water with 137 Cs and by the Fenton system composed of Fe-EDTA, ascorbate and H 2 O 2 . Radiolytic °OH caused a dose-dependent loss of tryptophan, production of dityrosine and carbonyl groups, dimerization and/or extensive aggregation of β 2 GPI. It ensued a reduction in affinity binding to cardiolipin liposomes and loss of β 2 GPI-dependent autoantibody binding to immobilized cardiolipin. Patient anti-β 2 GPI antibodies segregated into two groups based on the effect in the β 2 GPI-ELISA of β 2 GPI pretreatment with radiolytic °OH : enhancement or suppression of IgG binding in groups A (common type) and B (rare subset), respectively. The avidities of group A antibodies for fluid-phase β 2 GPI were low but increased in a dosedependent manner upon β 2 GPI irradiation, in relation to protein crosslinking. Distinguishing features of group B antibodies included higher avidities for fluid-phase β 2 GPI that was no longer recognized after °OH treatment, and negative anticardiolipin tests suggesting epitope location near the phospholipid binding site. The °OH scavengers thiourea and mannitol efficiently protected against all above changes. In contrast, the Fenton system induced no major alteration in the structure and functions of β 2 GPI. Thus, oxidative modifications of β 2 GPI via °OH attack of susceptible amino acids alters phospholipid binding, and modulates recognition by autoantibodies depending on their epitope specificities. These findings may be of clinical relevance for the generation and/or reactivity of anti-β 2 GPI antibodies. The precipitation by perchloric acid is usually the first step in the isolation of β2GPI used in the ELISA for anti-β 2 GPI antibodies. Perchloric acid inhibits plasmin and denaturates most proteins except for those being very basic. The aim of our study was to evaluate the common procedure for the isolation of β2GPI with special emphasis on the precipitation step with perchloric acid. The precipitation by perchloric acid, performed with different timing (3, 18 or 50 minutes) was followed by affinity chromatography on heparin, concluded by cationic exchange chromatography. Elution with the Na+ gradient (linear 0.05-0.65M) led to three distinct protein peaks. Each peak was isolated and analysed separately by 1./denaturated polyacrylamide electrophoresis, 2./rocket electrophoresis with rabbit polyclonal anti-β2GPI and 3./ELISA with 6 SLE and/or APS patients' sera, previously determined by the standard anticardiolipin and anti-β2GPI ELISA. In the ELISA all 9 proteins were used at the same concentration, determined by colorimetric reaction. The protein from the 2 nd peak exhibited a molecular weight of 50 kDa, corresponding to both molecular weight markers and reference β2GPI (Tincani, Brescia Italy). Both the protein from the 1 st and 3 rd peak exhibited a molecular weight of about 55 kDa. The same result was observed after all three different precipitations. In rocket electrophoresis, the proteins from the 2 nd and 3 rd but not from the 1 st peak reacted with polyclonal rabbit anti-β2GPI antibody. There were no diferences in the activities among the isolates obtained by the different precipitation timing. In the ELISA, the proteins from the 2 nd and 3 rd but not from the 1 st peak reacted with human anti-β2GPI antibodies. Differences among the isolates obtained by different precipitation timing were observed. The protein from the 2 nd peak obtained after 3-minute precipitation reacted 2 to 10 times stronger with different patients' sera than the protein from the 3 rd peak (from the same isolation). Proteins obtained after 18-minute precipitation reacted more weakly than did the proteins from the isolation after 3-minute precipitation, but the protein from the 2 nd peak gave still 2 to 6 time higher results than the protein from the 3 rd peak. The proteins from the 2 nd and 3 rd peaks after 50-minute precipitation reacted almost equally; the protein from the 3 rd peak after 50-minute precipitation reacted stronger than the same protein either after 18-minute or 3-minute precipitation.
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In conclusion, the precipitation with perchloric acid followed by affinity purification on heparin and cation exchange chromatography with linear Na+ gradient (0.05 to 0.65M) yielded three different proteins, out of which one was antigenically nonactive and two were antigenically active with anti-β2GPI antibodies. The time of precipitation influenced the antigenic properties of the two proteins with the same antigenic specificity but different molecular weight. Antibodies to β 2 -glycoprotein I /β 2 -GP I/, prothrombin /Pt/ and antithrombin III /AT III/ are not strictly speaking antiphospholipid antibodies, but they are closely associated with this pool of antibodies. The "marker" and prognostic significance of these antibodies have been recently widely discussed.
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The aim of the presented study was to determine whether the anti-β 2 -glycoprotein I, anti-Pt and anti-AT III antibodies possess "marker" and prognostic value in APS syndrome. The presence of the serum antibodies to these serum proteins, six selected phospholipids /including cardiolipin/ and Lupus antycoagulant have been tested and correlated with such clinical manifestations of the antiphospholipid syndrome /APS/ like: thrombotic events, fetal loss, trombocytopenia and livedo reticularis. The study covers 83 sera of the patients with various diagnoses /in 11 SLE, 43 SLE + APS /SAPS/ and 29 in PAPS/. The antibodies to β 2 -glycoprotein I in 21% of the SAPS cases and in 24% of the PAPS cases have been found and in none of the SLE without APS syndrome sera. The antibodies to Pt are present in 20% and to AT III in 15% of the tested sera. The correlation of antibodies to negatively charged phospholipid, LAC and anti-β 2 -glycoprotein I seems to be evident. Also significant increasing of the frequency of the appearance of selected clinical manifestations in the group of the anti-β 2 -glycoprotein I, anti-Pt and anti-AT III -positive sera was observed, especially fetal loss, livedo reticularis and thrombocytopenia. It seems to us the anti-β 2 -glycoprotein I, anti-Pt and anti-AT III antibodies are very promising "marker" for APS and possess also prognostic value. Results: Significant (more than twice) decreasing the amount of platelets of NZB/NZW F1 mice, elongation of parameters of the coagulation tests (APTT 40,0 ± 2,7 sec, control 27,6 ± 2,5 sec) (P < 0,01), decreasing the concentration of fibrinogen (1,1 ± 0,2 g/l, control 5,2 ± 0,6 g/l), increasing the level SFMC (28,1 x 10-2 ± 1,6 g/l, control 8,9 x 10-2 ± 1,03 g/l), increasing the parameter of spontaneous platelets aggregate (20,3 ± 1,96 %, control 2,5 ± 0,6 %) and aggregate of platelets with ADF (12,8 ± 1,3 %, control 9,0 ± 0,8 %) decreasing the aggregate with collagen (4,4 ± 0,6 %, contol 9,3 ± 0,8 %) were registered. The concentration of "plasma" serotonin was increased (0,065 mcg/ml, control 0,042 mcg/ml), the level of cortisol was considerably reduced (0,4 ± 0.09 mcg/ml, control 1,03 mcg/ml). The correlation between increasing the concentration of "plasma" serotonin, increasing the parameter of the spontaneous aggregate of platelets, increasing the concentration of SFMC, elongation of the coagulation tests and decreasing the concentration of "platelet" serotonin were marked. By the electronic microscopy the distrophy of endothelium is registered.
P85 Differences between active immunoinflammatory and postinfectious fibromyalgia (FM)
Conclusion:
Thus the endothelial damage of NZB/NZW F1 mice was accompanied by the expressed activation of a system of hemostasis, amplifying the aggregate of platelets and increasing the release of serotonin from them. At the same time the significant decreasing the concentration of cortisol was found. These disorders of hemostasis are typical for DIC syndrome. Therefore, it is possible to use NZB/NZW F1 mice as an animal model for study of disorders of hemostasis, including DIC syndrome, for the patients with SLE. In rheumatoid arthritis (RA), an excess of proteolytic enzymes secreted at the synovium-cartilage junction results in the invasion of the articular cartilage by synovial cells. The aims of the present study were to investigate the effects of overexpression of TIMP-1 and TIMP-3 on: 1) the invasive behaviour of rheumatoid fibroblastslike synoviocytes and 2) cell proliferation and apoptosis. The day before the experiments, the synoviocytes were infected with adenoviral vectors encoding TIMP-1 or TIMP-3 or with a control vector (AdLacZ). A Transwell system was used to study invasion of the cells. After 3 days, the invaded cells were counted using a microscope. Proliferation was assessed by measuring 3H-thymidine incorporation and cell counting. Apoptosis was assessed at 1-4 days after transduction using an Annexin V-FITC kit. Both TIMP-1 and TIMP-3 overexpression resulted in a significant reduction, respectively 60% (P < 0.001) and 80% (P < 0.001), of invasiveness of the synoviocytes as compared to the AdLacZ-transduced cells. In all cases, TIMP-3 was superior to TIMP-1 (P = 0.02). Cell proliferation was significantly reduced by TIMP-3 overexpression (40%; P < 0.05) and to a lesser extend by TIMP-1 (20%; P < 0.05) as compared to AdLacZ. There were little differences in % of apoptotic cells between the non-transduced, AdTIMP-1, AdTIMP-3 or Ad LacZ transduced cells up to 4 days after transduction. A maximum of 15% of the AdTIMP-3 transduced cells were in apoptotis as compared to a maximum of 12% in the other conditions. These results show that the invasive behavior of RA-FLSs can be strongly inhibited by overexpression of TIMPs. Both MMP inhibition and a reduction of proliferation appear to contribute to this effect. The superior effect of TIMP-3 may be due to a stronger effect on proliferation or to differences in the inhibitory profile of TIMP-1 and TIMP-3. To limit joint destruction in rheumatoid arthritis, inhibition of cartilage invasion by the pannus tissue by TIMP overexpression may be a useful approach. 
Poster Discussion
Departments of Laboratory Diagnosis and *Internal Medicine, University Graz, Austria
Objective: Leflunamide has been proven to be efficient in reducing joint inflammation and destruction in patients with rheumatoid arthritis (RA). This study was conducted to examine effects of leflunamide on serum levels of matrixmetalloproteinases MMP1 and MMP3 in patients with RA. Methods: In a prospective clinical trial, we measured in 24 patients suffering from RA, as defined by ACR criteria, serum activities of MMP1 and MMP3 by means of ELISA. Analysis of MMPs was performed before and after a treatment period of approximately 3 months (84 + 14 days, mean + SD) with leflunamide. Additionally, conventional inflammatory parameters (CRP, ESR) and clinical data of RA activity were determined.
Results:
Leflunamide treatment lead to a highly significant reduction of MMP1 serum activity (p < 0.001), whereas MMP3 values were not influenced. Furthermore, the number of painful (p < 0.01) and swollen (p < 0.05) joints decreased significantly as well as clinical inflammatory joint activity scores (GLASS, p < 0.001) and levels of CRP (p < 0.05).
Conclusion:
In accordance with recent data, leflunamide is effective in reducing the clinical inflammatory activity of RA, and in decreasing the activity of matrix-degrading factors like MMP1. The differential effect of this immunomodulative drug on MMP1 and MMP3 will be explored in further investigations. Rheumatoid Arthritis (RA) is associated with progressive joint destruction, functional disability and decreased life expectancy. Althought the underlying cause of RA is unknown, TNF-alpha, a proinflammatory cytokine, contributes to the pathogenesis of synovitis and joint destruction. Anti-TNF-biological response modifiers, such as Etanercept a recombinant human TNF receptor fusion protein, suggest that TNF-alpha-inhibition is a viable approach to control disease activity in RA. Considering the pivotal role TNF alpha plays in the first line defense against bacterial and fungal infections by polymorphonuclear leucocytes (PMN) it seems important to focus on the PMN function in RA patients, treated with Etanercept. Since a 29% increase in infections of the upper respiratory tract under TNF-alpha blockade has been reported, we investigated inflammatory parameters related to PMN-activity in 6 RA-patients, before and after 3-months of Etanercept treatment without altering their methotrexate and/or glucocorticoid-medication. The migration of the neutrophils was measured with a standardized whole blood membrane filter assay with and without stimulation by the chemoattractant fMLP. The percentage of migrating PMN (total migration index,TMI) and the relative penetration depth into the filters (distribution characteristics, DC) served to characterize the migratory behaviour of neutrophils. To estimate in vivo granulocyte activation, neutrophil elastase was measured in plasma from RA patients. In addition, PMN-blood count and Creactive protein as a marker of disease activity, were analysed. TNFalpha blockade significantly (p < 0,03) reduced the spontaneous and fMLP stimulated median TMI (15.2 vs. 10.9 and 16.5 vs. 11,4, respectively). Moreover the spontaneous and the fMLP-stimulated median DC was reduced under Etanercept-treatment ( 21.1 vs. 5.9, P < 0.03 and 20.5 vs. 6.6, P < 0.06 respectively). Interestingly, these values were still within the normal range of migratory activity. Furthermore, TNF blockade significantly reduced the median plasma elastase levels ( 252 vs. 108, p <0,04), as well as the median C reactive protein levels ( 21 vs. 7 P < 0,035) and the median number of polymorphonuclear leucocytes ( 7.73 vs. 4.58, P < 0.0001). Of note, plama elastase levels as a sign of systemic PMN-activation were still above the normal range. During the observed treatment period all patients showed an improvement in the inflammatory symptoms of RA ( 2 had a 70% ACR-response, 3 a 50% and 1 a 20% ACR response). No patients had signs of bacterial or fungal infections. In conclusions, TNF alpha blockade did not suppress PMN migratory activities to levels that are assosciated with higher incidences of infections. Objectives. The recent development of AAV vectors (adeno-associated virus) offers new perspectives for cytokine gene transfer in RA as they are non pathogenic and allow long term transgene expression in vivo. Moreover, we propose to regulate vIL-10 expression with tetracycline derivative (tetON system). The purpose of this study was to assess the potential long-term gene expression regulation of a recombinant AAV vector expressing vIL-10 in human rheumatoid synovial tissue and its efficiency in collagen-induced arthritis (CIA).
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Methods. The AAV-tetON-vIL10 vector contains two transcriptional units oriented in opposite directions, with a central bi-directional SV40 polyA. Sequences encoding the transcriptional activator rtTA, which confers doxycycline transgene induction, is inserted downstream a retroviral LTR promoter. A minimal human CMV promoter, flanked with tetracycline operator motifs, controls the transcription of vIL-10. Human RA synoviocytes were infected in vitro with AAVtetON-vIL10 (500 MOI) and vIL-10 secretion was assessed by ELISA after addition of 5 µg/ml doxycycline (dox). Therapeutic efficiency of the vector was achieved after intra-muscular injection (1.5 x 10 9 pi) in DBA1 mice with CIA in the presence of doxycycline in the drinking water (0.2 mg/ml).
Results. Viral IL-10 secretion by RA synoviocytes was increased 40-fold in presence of dox (233 ng/ml/10 6 cells) and returned to basal level 24 hr after dox removal. In CIA, serum vIL-10 increased to 0.38 ng/ml, 5 weeks after gene transfer in animals under diet dox.
RT-PCR analysis showed vIL-10 transcription in the muscle up to 14 weeks, without diffusion in other organs. We observed a decrease of CIA incidence (30% versus 89% in AAV-GFP injected control group) and of paw swelling (1.68±0.04 versus 1.81±0.15 on day 35 post-immunization, P < 0.0003). 18 IgG, were used to treat CIA mice in a therapeutic protocol (after disease onset). The effect on disease severity (visual scores) as well as parameters of cartilage and bone destruction were evaluated. Results: Clinical scores were significantly reduced after IL-18 blockade (rhIL-18BP 1 mg/kg, P < 0.001, n = 13; rhIL-18BP 0.25 mg/kg, P < 0.05, n = 7; anti-IL18 IgG, 2 mg, P < 0.05, n = 9, Mann Whitney test, treated versus placebo groups). Histological examination showed cartilage protection (decrease erosion scores, P < 0.05) that was accompanied by significantly reduced levels of serum cartilage oligomeric matrix protein (an indicator of cartilage turnover) and VDIPEN expression (a neoepitope present after digestion by matrix metalloproteinases). X-ray analysis of joints provided evidence of reduced bone erosion. Serum IL-6 levels were diminished in the treated animals.
Conclusions:
These results clearly demonstrate that blocking endogenous IL-18 is therapeutically efficacious in the CIA model and support the use of IL-18 neutralisation as a novel cartilage and bone protective therapy for the treatment of destructive arthritis. Recombinant hIL-18BP could therefore represent a new diseasemodifying anti-rheumatic drug that warrants testing in clinical trials in patients with rheumatoid arthritis.
P93 Digital vasculitis in a patient with rheumatoid arthritis: good response on anti-TNF blockade F van den Hoogen, A den Broeder, M Zandbelt and L van de Putte
Department of Rheumatology, University Medical Center St. Radboud, Nijmegen, The Netherlands
Rheumatoid arthritis (RA) may be complicated by vasculitis. Vasculitis usually affects small vessels of the skin causing nailfold infarcts, but may also affect larger vessels and cause severe damage to internal organs. In such cases, treatment with high doses of corticosteroids or other immunosuppressive drugs may be necessary. TNF-alpha blockade has been shown to be an effective and safe treatment for RA, but thus far no reports have addressed the effect of TNF-alpha blockade on extra-articular manifestations of RA, such as vasculitis. We report a patient with RA and nailfold infarcts which repeatedly disappeared for several weeks following monthly i.v. injections with an anti-TNF alpha receptor fusion protein.
A 46 year old woman was diagnosed as having rheumatoid factor positive, erosive RA in 1982. Due to the uncontrollable disease she was included in 1994 in a study with Ro 45-2081, a fusion protein combining two p55 TNF receptors with the Fc component of an IgG human antibody (Roche, Basel, Switzerland, sTNFR:Fc). After a three months placebo controlled phase she was treated with 50mg sTNFR:Fc every four weeks. Clinical response was impressive with swollen joint counts decreasing from 32 to 5 and C-reactive protein CRP levels declining from 95 at baseline to 20 after the first injection. Low disease activity was sustained for the following years. Besides sTNFR:Fc her medication consisted of oral prednisone 5 mg a day and occasionally paracetamol 500 mg. In the spring of 1999 she first noticed nailfold infarcts on the fingers of both hands. These lesions disappeared after every injection of sTNFR:Fc and reappeared three weeks thereafter when the clinical effects of sTNFR:Fc were decreasing. This effect on the digital vasculitis has been well documented during several cycles of sTNFR:Fc administration.
Conclusion:
The prompt disappearance of nailfold infarcts after sTNFR:Fc administration observed in our patient strongly suggests a therapeutic effect of sTNFR:Fc on active vasculitis. This observation raises the question whether blocking of TNF-alpha might also be effective in more severe forms of vasculitis and possibly other extra-articular manifestations of RA, some of which are life threatening and are currently treated with high doses of corticosteroids and immunosuppressive drugs.
P94 Effect of osteoprotegerin and pamidronate treatment in transgenic mice overexpressing human TNF
Rheumatoid arthritis (RA) is characterized by progressive joint destruction resulting from chronic inflammation. Recent studies suggest that bone-resorbing osteoclasts formed in the synovium play an important role in bone destruction in RA. We studied the effect of anti-resorptive treatment with osteoprotegerin and/or pamidronate compared to TNF blockade with infliximab on the development of erosions in TNF overexpressing mice. Systemic treatment with osteoprotegerin (OPG), pamidronate, both osteoprotegerin and pamidronate, infliximab or phosphate buffered saline (PBS) was carried out by intravenous injection . Treatment was initiated at the time of onset of arthritis and continued over 35d. Clinical, serological, radiological and histological outcomes were assessed after treatment. Clinical improvement, as assessed by reduction in paw swelling was only seen in the infliximab treated group. X-Rays of the hind paws were performed to quantify erosive changes. Erosions were detectable in each joint compartment Grading of erosions was performed analogous to the Larsen score. There was a marked and significant (P < 0.05) reduction in the Larsen scores of mice treated with OPG (-54%), OPG and pamidronate (-64%) and infliximab (-66%). Microscopic examination of decalcified joint tissue sections using a semiquantitative method, revealed a significant (P < 0.05) reduction in the extent of erosions in all treatment groups (OPG: -56%; pamidronate: -53%; OPG + pamidronate: -81%; infliximab -46%) when compared to controls. These data suggest that anti-resorptive treatment may have a significant potential in TNF-mediated bone destruction. 
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Institute of Clinical Immunology and Transfusion Medicine, University of Leipzig, Germany
Background: In pathogenesis of rheumatoid arthritis, fibroblasts are considered to be a crucial cell population for disease progression as well as joint destruction. Following intraarticular injection into SCID mice, isolated human rheumatoid synovial fibroblasts have been shown to induce a destructive arthritis (hu/mu SCID arthritis). Although exclusively human synovial fibroblasts were able to induce this arthritis, cartilage destruction was caused by murine fibroblast like cells in this model. Therefore, we have isolated a murine destructive fibroblastoid cell line and established a cartilage destruction model. Material and methods: LS48 cell line was examined for morphological, ultrastructural, immunological, and functional parameters. Furthermore, cartilage destruction was induced by intraarticular application of LS48 cells into SCID mouse knee joints. Mice were monitored for joint swelling, serological parameters and by radiological methods. Finally, immunohistochemistry and histology were used to characterize morphology of cartilage destruction. Results: LS48 was shown to present characteristics of a fibroblastlike cell. Secretion of interleukin-6 and tumor necrosis factor-alpha revealed similarities to human invasive rheumatoid synovial membrane fibroblasts. Installation of 5 x 10^5 cells into SCID mouse knee joints caused a rapid progressive process causing cartilage destruction within 10 days. Morphology revealed infiltration of fibroblast like cells into the cartilage. Conclusions: Induction of cartilage destruction by intraarticular application of these murine fibroblast like cells is a rapid and highly reproducible model for investigation of cartilage destruction in arthritic joints. This provides an excellent possibility to investigate relevant processes and new therapeutic strategies for rheumatoid arthritis in an easy-to-handle animal model.
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Infiltrate analysis of rheumatoid synovial tissue before and after high does chemotherapy and autologous stem cell transplantation RJ Verburg, R Flierman, EWN Levahrt, F van den Hoogen*,
FC Breedveld and JM van Laar
Departments of Rheumatology, Leiden University Medical Center and *University of Nijmegen, The Netherlands
Objective: To investigate the effects of high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) on the synovial infiltrate in rheumatoid arthritis. Methods: 8 patients with erosive, refractory, progressively rheumatoid arthritis, were treated with HDC (cyclophosphamide 200 mg/kg) and CD34 enriched selected ASCT. Biopsies of synovial tissue from a clinically involved knee were obtained by arthroscopy before and three months after HDC and ASCT. Immunohistochemistry was performed and blindly scored on a five point scale (0-4) using MoAbs specific for the following markers: CD3, CD4, CD8, CD25, CD27, CD45RA, CD45RO, CD45RB, CD19, CD20, CD22, CD38, CD5, CD68, HLA-DR, CD62L, CD62E, CD56 and CD55.
Results: There were no statistical significant differences (Wilcoxon's signed rank test) when the results before and after transplantation were compared. However when patients were divided in clinical responders (ACR > 50%, n = 5) and non-responders (ACR < 20%, n = 3) statistically significant differences with respect to several Tcell markers were found (Table) . Three patients with rheumatoid arthritis on newer immunmodulating therapy, developed acute glomerulonephritis. Two of the patients were treated with tumour necrosis factor blockade ( Etanercept, 25 mg sc. twice a week) and one with leflunomide (Arava, 20mg daily) in addition to the conventional medical treatment. All of the patients developed unexpected blood and urinary abnormalities, two of them after treatment with Etanercept for eleven-and one months respectively. Renal biopsies showed in, the patients with long term Etanercept treatment, focal proliferative glomerulonephritis with cellular crescents in 30% of all glomerular sections. The biopsy showed mesangial deposits of IgA. This patient was suspected clinically for subacute bacterial endocarditis, however all data were negative. In the other patient treated with Etanercept for only four weeks slightly diffuse mesangial proliferative glomerulonephritis was demonstrated. Electron microscopy of this biopsy showed distinct mesangial matrix changes "moth-eaten" appearance. In the patient treated with Arava during four weeks, biopsy showed focal proliferative glomerulonephritis with cellular crescents in 7% of all glomerular sections and with IgA mesangial deposits. Two of the patients thus had IgA glomerulonephritis. The diagnosis of the third one was inconclusive, as regard the present of IgA , but pathology could represent IgA glomerulonephritis in resolution.
The relation in time of sign of renal disease to the treatment with Etanercept and Arava makes it probable that renal disease was related to these drugs. It is generally assumed that IgA glomerulonephritis is caused by the deposition of immune complexes, but details of antigen(s) are in these cases unknown. We finally regard it as a possibility that the immunmodulation caused by these new drugs may facilitate silent infection and subsequently development of IgA glomerulonephritis. At least in long term treated patients this aetiology could not be excluded.
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The use of Ribomunyl ® in the immunomodulatory treatment of rats with adjuvant arthritis Methods: In a randomised, double blind, placebo controlled trial, between 1992 and 1996, 71 patients with acute reactive arthritis (ReA) triggered by a gastrointestinal or an urogenital infection were randomly assigned to receive ciprofloxacin or placebo twice daily for three months. There were no statistically significant differences in any variables during the 12-month follow-up. The aim of the present study was to evaluate the effect of ciprofloxacin on the late prognosis of ReA. We reviewed the long-term outcome in 56 (79%) of 71 patients 4-8 years after the acute phase of ReA. The patients suspected to have inflammatory back pain (IBP) were further evaluated using the MRI of the sacroiliac joints. Six of the 10 patients with chronic spondyloarthropathy (SpA) were assessed by Tclabelled leucocyte scintigraphy to search for the association between gut inflammation and SpA. Results: Two patients (7%) in the active treatment group and 10 patients (36%) in the placebo group had developed chronic disease. Ankylosing spondylitis (AS) was diagnosed in 3 patients (11%) in the placebo group. One patient (4%) in the active treatment group had psoriatic arthritis. None in the active, 4 (14%) in the placebo group were assessed as having undifferentiated spondylarthropathy (USpA, ESSG, Amor's criteria). Three of these USpA patients had sacroiliitis, 1 had chronic oligoarthritis and one male patient had chronic oligoarthritis and bilateral sacroiliitis. Two patients (7%) in the placebo group suffered from chronic enthesiopathy (achilles tendon Results: In the early treatment group the increase in the median Sharp score in the SE+ group was 1.0 to 5.0 in contrast to 1.0 to 3.0 in the SE-group (P>0.5). However, in the pyramid group the increase in joint damage was 0.0 to 16.0 in the SE+ group in contrast to 0.0 to 5.0 in the SE-group (P < 0.005). On the other hand, in the RF+ group of the early treatment group the increase in joint damage was 1.0 to 6.5 in contrast to 1.0 to 1.0 in the RF-group (P < 0.005). In the pyramid group the increase in joint damage was 0.5 to 17.0 in the RF+ in contrast to 0.0 to 3.0 in the RF-group (P < 0.005).
Conclusion:
This study shows that early anti-rheumatic drug treatment abolishes the effect of HLA class II alleles on extend of joint damage in early RA patients. Objective: T cell specific adapter protein (TSAd) is involved in the negative control of T cell activation. The SH2D2A gene encoding TSAd is located on chromosome 1q21 which has been implicated in susceptibility to experimental autoimmune disorders in the mouse (chronic allergic encephalomyelitis and collagen-induced arthritis).
Recently we found that short alleles of the SH2D2A gene promoter are associated with multiple sclerosis (MS). The aim of our study was to investigate whether the SH2D2A promoter polymorphism contributes to the genetic susceptibility to develop juvenile idiopathic arthritis (JIA). Methods: DNA from 212 Norwegian patients with juvenile arthritis (categorized as systemic (n = 18), poly-RF+ (n = 12), poly-RF-(n = 61), oligo-(n = 87) and extended oligoarthritis (n = 31)) and 279 healthy unrelated Norwegian controls were genotyped for a functional GA repeat polymorphism in the promoter region of SH2D2A gene using an ABI automatic sequencing machine (ABI PrismTM XL377) Results: The frequencies of the two shortest alleles GA13 and GA16 were increased among the JIA patients compared to the control; the GA13 significantly so (0.098 vs 0.053, OR=1,97, P = 0,0063). When we divided patients into subgroups only in the RFpositive polyarthritis group of patients there was no increases of any of the short alleles. All other subgroups of JIA showed an increased frequency of GA13, however only in the patients with oligoarthritis the increased frequency of GA13 allele reached significance (0.103, P = 0.017). When we analyzed the frequency of short alleles in relation to the occurrence of chronic iridiocyclitis (CIC) in the group of patients with oligoarthritis (n = 14), we found that 57% of the these patients carry at least one short allele compared to 46% of the patients without CIC (n = 73 The immune response to protein antigens depends on processing by antigen presenting cells and subsequent presentation of peptides to specific T cells by molecules of the MHC. In rheumatoid arthritis (RA) there is much evidence implicating a positive genetic association of the disease with several alleles of the DRB1 gene, characterised by a common amino acid sequence at position 70-74 ("shared epitope"). The most frequent of these alleles is DRB1*0401 with the sequence QKRAA, which is also present in the E. coli protein DnaJ. DnaJ and DnaK, a member of the HSP70 family, or their homologs in other species, together form an important chaperone machinery in bacteria and higher organisms, including man. It was proposed that the motif QKRAA might be involved in binding between DnaJ and DnaK, and also in binding of QKRAAcontaining DR $-chains to the human heat shock cognate protein HSC70. We used a T cell clone with a restriction pattern similar to the genetic association of RA, being specific for an epitope of the "-chain of the human acetylcholine receptor (AChR). It reacted with synthetic peptides presented by murine P388.D1 expressing the human DRA and DRB1*0401 (71Lys) or DRB1*0408 (71Arg), with slight preference for 0408. In contrary, the recombinant "-chain (r1-437) or AChR obtained from human muscle extracts were much better presented by 0401. This preference depended entirely on the presence of E. coli DnaK or human HSC70 in the antigen preparations; the response was lost, if HSP70 molecules were removed, and reconstituted by their addition. We conclude that efficient processing of the long protein requires the presence of a member of the HSP70 family, which besides protecting the epitope, interacts intracellularly well with 0401, but less well with 0408 $-chains, and thus participates in the process of peptide loading. This mechanism might be of importance for immune responses against foreign antigens (advantage of DRB1*0401) as well as against autoantigens (disadvantage of DRB1*0401). Results: Apoptosis level in RA synovium is signficiantly higher in late cases compared with early ones (P = 0,001), while macrophage population significantly decreases during disease progession (P = 0,003). Macrophage score is negatively correlated with apoptosis level (R=-0,618; P = 0,0088). In contrast, no correlation could be observed between apoptosis and monokine expression or T cell score. Discussion: Low level of apoptosis in early RA cases suggests an ineffective cell death mechanism that ultimately contributes to cell accumulation into the joint and propagation of the inflammatory response. Apoptosis is restored during disease progression, in parallel with a decrease of the macrophage number. These findings suggest apoptosis as a possible marker for early RA and a promising therapy target. The control of phosphorylation of CK2 target sites has long been a matter of controversy. We have demonstrated that phosphorylation of the ribosomal P protein CK2 sites is reliably measurable by 2D western blotting of whole cell lysates. Physiologically, phosphorylation of the CK2 sites of the P proteins is necessary for the elongation phase of protein translation, which can be used as an indirect parameter of P protein function. Based on previous data showing that crosslinking of CD95 and hyperthermia lead to the dephosphorylation of the ribosomal P protein CK2 phosphorylation sites and decreased protein synthesis, which was associated with the induction of apoptosis in Jurkat cells, we examined whether similar mechanisms are initiated when apoptosis is induced by inhibition of the PKC pathway. In Jurkat cells and freshly isolated peripheral blood T cells, rapid dephosphorylation of the ribosomal P proteins P0, P1 and P2 was induced by low concentrations of chelerythrine, a specific inhibitor of PKC. Neither of the specific PKC activators thymeleatoxin or PMA were able to prevent the dephosphorylation. Inhibition of intracellular Ca2+ release by TMB-8 also induced dephosphorylation of the P proteins, which is compatible with the requirement of intracellular Ca2+ for classical PKC isozyme activity. Chelerythrine also induced apoptosis in Jurkat cells, which was prevented by zVAD-fmk and ZnCL2, though these agents did not inhibit the dephosphorylation of the P proteins. The effects of chelerythrine were not due to altered CK2 activity, and there was no evidence that the cAMP-dependent PKA, ornithine decarboxylase, or protein phosphatase 2A pathways were involved in signaling leading to P protein dephosphorylation. The dephosphorylation of the P proteins was accompanied by markedly reduced whole cell protein synthesis, which, in parallel with dephosphorylation of the P proteins, was not affected by zVAD-fmk or ZnCl2. To delineate the mechanism(s) by which the PMN life span is prolonged, we studied the response of PMN to F(ab') 2 fragments of anti-FcγR (CD16) monoclonal Ab. CD16 engagement decreased apoptosis and prevented the up-regulation of β2 integrins, particularly CD11b which is the α chain of complement receptor 3, and CD18 which is its β chain. The expression of mRNA for G-CSF and GM-CSF was induced. Release of these chimiokines followed CD16 stimulation, suggesting an autocrine involvement of survival factors in the rescue of PMN. The levels of G-CSF and GM-CSF paralleled the amounts of CD16 monoclonal Ab used to stimulate the cells. This set off a partial reduction of caspase 3 activity and was associated with downexpression of Bax. It was shown that anti-G-CSF and anti-GM-CSF Ab inhibited these events, while anti-TNFα was ineffective. Overall, apoptosis of aged PMN can be modulated by signalling through FcγR, which may occur in patients with PMN-binding autoAb. This might be particularly relevant in the synovial fluid of patients with RA. onset of autoimmunity, and it is a general observation that autoimmune diseases are associated with distinct profiles of autoantibodies. During the last five years there has been a growing interest in finding possible connections between apoptosis and autoimmunity. It has been hypothesized that the recognition, uptake, processing, or presentation of modified self-antigens may promote autoantibody production. At present, many autoantigens have been found that are modified (i.e. cleaved, phosphorylated or dephosphorylated) during apoptosis. Using autoimmune patient sera in immunoprecipitation and Western blotting assays with cell extracts derived from nonapoptotic and apotptic cells, we identified sera reactivities specific for (novel) modifications of autoantigens. In this paper we give an overview of our studies on human recombinant autoantibodies derived from patients suffering from rheumatic diseases. Furthermore, we describe the generation of recombinant chicken antibodies specific for human autoantigens that will also be used to study these antigens and (apoptotic) modifications thereof in more detail. We selected human recombinant antibodies from patient phage display scFv combinatorial antibody libraries (complexity of 107 or higher) derived from peripheral blood or bone marrow lymphocytes of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma (SSc). Next to the human patient libraries we also used chicken libraries made from spleens of animals immunized with 7 human (auto)antigens simultaneously. Screening of both patient and animal derived libraries with recombinant or purified autoantigens resulted in several recombinant monoclonal human and chicken (auto)-antibodies. From our SLE patient libraries, autoantibodies against U1snRNP components U1-A, U1-C, U1-70k and U1-RNA were selected. Moreover, from our SLE libraries we selected anti Ro52 and anti ribosomal P protein antibodies, and from both our SLE and scleroderma libraries we selected anti-La and anti a-fodrine recombinant antibodies. From our RA patient libraries antibodies specific for RA related peptides were obtained. All human scFv clones obtained were characterized by ELISA, immunoprecipitation assays, western blotting, epitope mapping and of some clones the affinities were measured and competition experiments with patient sera were performed. Sequence analysis was performed to study the germline usage. All chicken clones were sequenced and analyzed by LIA, Western blot and ELISA. We will discuss characteristics of some of the selected scFv's i.e. epitope mapping, germline gene usage, and competition experiments with patient sera. The phage autoantibodies selected from autoimmune patient libraries were also analyzed for their specificity for (apoptotically) modified forms of their target autoantigens by Western blotting and immunprecipitation assays using apoptotic cell-extracts. Some antiLa, anti-70K and anti-RA peptide scFv's recognized (apoptotically)-modified forms of their target antigens.
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Conclusions:
The use of antibody phage display proves to be an extremely helpful technique in studying autoantibodies and autoantigens. Modifications of autoantigens (by apoptosis and/or necrosis) seem to play a major role in the ontogeny of autoimmune diseases. Currently, by using antibody phage display libraries in combination with patient sera we continue our search for possible modifications of autoantigens involved in the ontogeny of autoimmune disease. 
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Abstracts of invited lectures
L1
The impact of DNA chip technology on molecular medicine
KK Wilgenbus
Boehringer Ingelheim R&D, Austria
The recent popularity of DNA chip technology has been fostered by the increasing demand for new tools, which allow the simultaneous analysis of large numbers of nucleic acid hybridization experiments in a timely fashion. The development of DNA chip-based assays has been strongly driven by modern approaches aiming at the comprehensive analysis of multiple gene mutations and expressed sequences. The broad range of current DNA chip applications include the detection of pathogens, the measurement of differences in the expression of genes between different cell populations as well as the analysis of genomic alterations such as sequence or copy number alterations of disease related genes or single nucleotide polymorphisms. A brief overview of the impact of DNA chip technology on the field of Molecular Medicine will be provided, followed by a more detailed presentation on DNA chip technology for large-scale differential expression profiling. Protein microarrays are produced by the application of thousands of proteins and peptides to the surface of a glass microscope slide using a robotic arrayer. We have developed an array containing the major SLE antigens including dsDNA, ssDNA, Sm, Ro, La, histones, and Sm/RNP, along with several other common disease-specific autoantigens. Arrays are probed with serum from disease or control patients, followed by incubation with fluorescently labeled, antihuman secondary antibody. Our array analysis reveals distinct autoantigen response patterns in individual SLE patients. ELISA, immunoprecipitation, and western blot analysis validate our array results. Protein autoantigen arrays represent a powerful tool which may be used to perform comprehensive studies of the breadth of epitope spreading, as well as the fine specificity of the autoantibody response. The large scale of our protein arrays allows us to examine reactivity patterns against a much wider range of autoantigens than was previously possible with more traditional methods. Our ability to distinguish autoantibody specificity patterns using autoantigen microarrays will provide further insight into the role of autoantibodies in disease progression and pathogenesis in subsets of SLE patients with distinct autoantibody responses.
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L5
The integration of functional genomics, combinatorial chemistry and nanotechnology into a miniaturized drug discovery process
M Auer
Novartis Forschungsinstitut GmbH, Dermatology, Fluorescence based HTS-Technology Program, Vienna, Austria
Future concepts in miniaturized HTScreening technologies will concentrate on making optimal use of the two emerging technologies, combinatorial chemistry and functional genomics. To effectively exploit compounds from highly-parallel combinatorial synthesis and the high number of new target proteins from functional genomics, Novartis and Evotec BioSystems developed the CONA-BSP (confocal nanoscanning -bead scanning picking technology) as a novel high throughput -low hit-rate HTS process. In combination with the Novartis proprietary AIDA-Technology, quantitative on-bead confocal fluorescence screening can be combined with off-bead confirmation via a series of fluorescence techniques such as fluorescence anisotropy, or rotational correlation time applied to equilibrium binding studies. Single molecule fluorescence spectroscopy and confocal nanoscanning/AIDA technology provide an optimal combination for a miniaturized automated uHTS process with high mechanistic resolution in functional and coupled assay systems. Recombinant proteins can be very potent, but their therapeutic application can be strongly hampered by inappropriate distribution, dosage, kinetics or toxic effects. Targeted delivery of proteins such as cytokines would be strongly desirable. DNA therapeutics comprise the delivery of genetic information on a piece of DNA as therapeutic prodrug. This prodrug can be transcribed and translated into a protein (the actual drug) within the target cells, preferably in a tissue-specific and bio-regulated fashion. Basically, two types of nonviral gene transfer systems [1] have been developed: particle-based systems, with DNA packaged into cationic lipids or polymers; and physical techniques which are based on combining DNA with a physical device. Intramuscular administration of naked DNA has already proven as interesting concept for vaccination [2] , despite the low efficiency of the method. Two physical device technologies, electroporation and the gene gun, were found to enhance gene expression levels up to 1000-fold over injection of naked DNA alone. This enhancement has also recently been shown by several groups to trigger immune responses against defined antigens in several species [3] . We have generated particle-based systems that can target gene delivery and expression into distant target tissues. We use DNA polyplexes conjugated with cell-binding ligands such as transferrin for receptor-mediated endocytosis. The surface charge of complexes is masked by covalent coating with polyethylenglycol (PEG). Tumor targeting has been demonstrated in mouse models after systemic administration. With systemically applied tumor necrosis factor (TNF) alpha gene, tumor necrosis and regression of tumors was observed, but no systemic TNF-related side effects. Opportunities to apply local or systemic DNA therapeutics for inflammatory diseases will be discussed.
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Chromosome segregation one hundred years after Mendel´s rediscovery K Nasmyth
IMP, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
In eukaryotic cells, replicated DNA strands remain physically connected until their segregation to opposite poles of the cell during anaphase. This "sister chromatid cohesion" is essential for the alignment of chromosomes on the mitotic spindle during metaphase. Cohesion depends on a multisubunit protein complex called cohesin, which possibly forms the physical bridges that connect sisters. Proteolytic cleavage of cohesin's Scc1 subunit at the metaphase to anaphase transition is essential for sister chromatid separation and depends on a conserved protein called separin. We show here that separin is a cysteine protease related to caspases and that it alone can cleave Scc1 in vitro. By replacing one of Scc1's cleavage sites by that for a different site specific protease, we show that cleavage of Scc1 in metaphase arrested cells is sufficient to trigger the separation of sister chromatids and their segregation to opposite cell poles. The aetiology of systemic lupus erythematosus (SLE) is unknown. However, there is good evidence to support a genetic contribution in lupus, including a number of mouse strains that are genetically predisposed to develop lupus. Several groups have published genome-wide mapping studies on multi-case families. More than 15 intervals have been linked with SLE -they are large enough to contain several hundred genes; the aetiologic polymorphisms contained within them remain to be established. We are establishing a large collection of single case nuclear families with the aim of fine mapping the aetiologic polymorphisms. Using a candidate gene approach, we have examined several genes, which lie within the linked intervals. First, we identified genetic markers in the candidate genes. The inheritance of the markers in our nuclear families was then tested using the program TRANSMIT which compares the observed and expected rates of transmission of marker alleles (or haplotypes) from parents to offspring. A marked distortion away from random segregation indicates association with disease. We have hypothesised that genetic variation in the pentraxin genes, C-reactive protein (CRP) and serum amyloid component P (SAP) predisposes to SLE. These two genes are tightly linked on chromosome 1q21-23, a region linked to human SLE. Other evidence implicating these includes the defective CRP response in SLE and the presence of antinuclear autoimmunity in Sap knockout mice. We identified five novel single base pair polymorphisms (three in CRP and two in SAP) and tested these for evidence of association. Individuals from 354 families were studied. These data provide no evidence for a genetic contribution to human SLE from the pentraxin genes. When haplotypes across this locus were examined there was similarly no evidence of association. The defective CRP response in human SLE is unlikely to be related to variation at the CRP locus itself.
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The role of DNA in the pathogenesis of SLE
DS Pisetsky
Duke University Medical Center, USA Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antibodies to DNA. These antibodies serve as markers of diagnosis and prognosis as well as serological markers of disease pathogenesis. While designated as autoantibodies, SLE anti-DNA target sites that are widely conserved among DNA of both self and foreign origin. This crossreactivity, a feature that appears common among SLE antinuclear antibodies, raises the possibility that immune responses to DNA may arise from stimulation by foreign DNA. This possibility has gained credence from observations that DNA from bacteria has potent immunological properties. These properties include polyclonal B cell activation and induction of cytokines such as IL-12. Furthermore, sera of normal human subjects contain anti-DNA antibodies which selectively bind to DNA from certain bacterial species. Immunization experiments in mice fully support the possibility that bacterial DNA can initiate or sustain SLE anti-DNA production. Recently, studies in mice have demonstrated that self DNA has immunological activity and is not inert as has been widely assumed. As shown in in vitro experiments, DNA from mammalian species including human and bovine, can inhibit cytokine production induced by bacterial DNA and, in certain, systems, the cytokine response to LPS. As such, self DNA may play a regulatory role in immunity, inhibiting response in settings of tissue inflammation or destruction where self antigens are released from cells. These considerations suggest that anti-DNA responses in SLE could result from a crossreactive response to foreign DNA or an aberrant response to self DNA in which the inhibitory signals of mammalian DNA are insufficient or overcome. In either instances, models of SLE must take into account that DNA plays an active role in immune responses and, depending upon species and base composition, may be stimulatory or inhibitory.
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From perinuclear factor to citrulline, a target structure for autoantibodies in rheumatoid arthritis
G Serre
Department of Biology and Pathology of the Cell, INSERM CJF 96-02 IFR30, Purpan School of Medicine, Toulouse III University, Toulouse, France
Antiperinuclear factor (APF) and the so-called "antikeratin antibodies" (AKA), have been described 37 and 22 years ago, respectively. Now, their diagnostic value in Rheumatoid Arthritis (RA) was confirmed on thousands of patients.
In the past few years the molecular targets of these RA-specific serum IgG antibodies were identified : first those of AKA were shown to be acidic variants of filaggrin in human epidermis and (pro)filaggrin-related proteins in rat oesophagus epithelium ; secondarily the target of APF in human buccal mucosa cells was demonstrated to correspond to tissue-specific forms of (pro)filaggrin. APF and AKA were proved to constitute two overlapping subgroups of antibodies belonging to a same family of antifilaggrin autoantibodies (AFA). All these AFA-targetted proteins were demonstrated to be deiminated i.e. having their arginyl residues (arginines involved in peptidic bonds) transformed into citrullyl residues (citrullines). This posttranslational enzymatic modification is due to a peptidyl-arginine deiminase. AFA are unreactive with native recombinant human filaggrin but become highly reactive after enzymatic deimination of the protein. Moreover synthetic peptides derived from the human filaggrin sequence are reactive with AFA only when their arginyl residues have been substituted by citrullyl residues (citrullinated peptides). Therefore AFA are directed to peptidic epitopes in which citrullyl residues play a pivotal role, nevertheless the neighbouring residues are important since certain are permissive and participate to generation of AFA epitopes whereas others are non-permissive and make the reactivity with AFA impossible. Identification of the molecular targets of AFA allowed the development of new tests for their detection, using either (pro)filaggrin extracted from epithelia or deiminated recombinant filaggrins and/or filaggrin-derived citrullinated peptides. Several of these new tests prove to be highly efficient in the diagnosis of RA and largely more performant than the reference APF and AKA tests. They show that at least 2 out of 3 RA patients develop the very specific antifilaggrin B autoimmunity. It is well documented that cytokines have critical functions in regulating immune responses and remarkably, the number of cytokines continues to expand. One large family factors that includes many interleukins and interferons binds related receptors termed the Type I and Type II families of cytokine receptors. These receptors activate Janus kinases (Jaks) and Stat family of transcription factors. The essential and specific function of Jaks and Stats is particularly well illustrated by human and mouse mutations. For instance, mutations of human Jak3 results in severe combined immunodeficiency. These mutations are of interest in that they provide clues to Jak structure/function. Additionally, patients with mutations that allow for partial expression of the protein may have nonclassical clinical presentations in which autoimmune features are prominent. There are also a number of mechanisms by which cytokine signaling is attenuated. One important family of inhibitory molecules is the SOCS family. The possibility that the various components of the cytokine signaling pathway could be targeted to produce novel immunosuppressive compounds will be discussed.
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The pathogenesis of vasculitis
CGM Kallenberg
Department of Clinical Immunology, University Hospital Groningen, P.O.Box 30.001, 9700 RB Groningen, The Netherlands
In the secondary vasculitides, associated with infectious disorders, connective tissue diseases and other conditions, immune complexes play a major immunopathogenic role. Immune complexes are absent in most of the primary vasculitides. T-cells are, probably, involved in the large vessel vasculitides, particularly giant cell arteritis, whereas the small vessel vasculitides are associated with antineutrophil cytoplasmic autoantibodies (ANCA). Clinical observations, in vitro experimental findings, and in vivo data from animal experiments suggest that ANCA in those diseases, which are directed to proteinase 3 (PR3) or myeloperoxidase (MPO), are involved in their pathogenesis. Most in vitro studies have focussed on ANCA-induced neutrophil activation. More recently the interaction between ANCA, neutrophils and endothelial cells has been studied in flow systems. ANCA appear to activate integrin-mediated adhesion of neutrophils and adhesion-dependent degranulation. ANCA-induced monocyte activation has been studied to a lesser extent. The role of ANCA-specific T-cells is still under investigation. Epitope analysis showed T-cell reactivity to peptides from PR3 but no specific PR3 sequence could be identified that was preferentially recognized by T-cells of vasculitis patients compared to controls. In vivo experimental studies, in which an MPO-directed autoimmune response is generated, show the phlogistic potential of this response. Apoptotic neutrophils may, under certain circumstances, induce the induction of ANCA. Data from clinical and experimental studies suggest that ANCA alone are not sufficient to induce disease. Exogenous factors, in particular carriage of Staphylococcus aureus and silica exposure, may be involved as well. S. aureus products may elicit antibody responses resulting in focal immune complex deposition, e.g. in the kidneys. ANCA may aggregate the inflammatory response resulting in destruction of complexes and the development of severe necrotizing glomerulonephritis without immune deposits. Taken together, the interplay between genetic and exogenous factors may induce autoimmunity to myeloid enzymes which, in concert, lead to the clinical expression of the ANCA-associated vasculitides.
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The pathogenesis of osteoarthritis: potential targets for therapy
S Abramson
Department of Rheumatology & Medicine, Hospital for Joint Diseases, New York, USA
It is likely that the excessive production of cytokines, inflammatory mediators and growth factors by the inflamed synovium and activated chondrocytes play an important role in the pathophysiology of osteoarthritis. IL-1b and TNF-a can stimulate their own production and induce chondrocytes and synovial cells to produce other cytokines such as IL-8, IL-6, LIF, as well as stimulate proteases, nitric oxide (NO) and prostaglandin E2 (PGE2) production. NO and PGE2 are spontaneously produced by human osteoarthritisaffected cartilage. The excessive production of nitric oxide inhibits matrix synthesis and promotes its degradation. Furthermore, by reacting with oxidants such as superoxide anion, nitric oxide promotes cellular injury and renders the chondrocyte susceptible to cytokine-induced apoptosis. Although PGE2 is the predominant eicosanoid produced by OA cartilage, PGI2, PGD2, TXA2 and LTB4 are also spontaneously produced. These specific eicsoanoids exert diverse effects on matrix metabolism and gene expression that require detailed elucidation. Differential gene product analysis also reveals increased expression of osteopontin (OPN) and fibronectin (FN) mRNA in human osteoarthritis-affected. Osteopontin inhibits the spontaneous production of inflammatory mediators such as NO and PGE2. Therefore, inflammatory and anti-inflammatory molecules produced by OA chondrocytes can be targeted in future therapeutic stategies of OA.
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The role of "nurse-like cells" in bone resorbtion observed in patients with RA
T Ochi
Osaka University Medical School, Osaka, Japan Synovial stromal fibroblastic cells were histologically suggested to be derived from the mesenchymal fibroblastic cells migrating from the ajacent bone marrow space. The membrane structures, cytokine productions, and other bioligical charactceristics are very similar among those fibroblastic cells derived from these two origins. These 
University of Vienna, Vienna, Austria
Synovial stromal cells (e.g. fibroblast-like synoviocytes, FLS) are thought to play an essential role in the pathogenesis of inflammatory joint diseases, in particular in the destructive aspects of rheumatoid arthritis (RA). Recent evidence indicates that chromosomal alterations have a profound impact on cellular behavior, even in non-transformed cells. We therefore investigated whether or not alterations in chromosome number occur in FLS of patients with RA and osteoarthritis (OA). Synovial tissue was collected at the time of joint surgery from 21 patients with RA and 22 patients with OA. Synoviocytes were isolated by enzymatic dispersion. Interphase fluorescence in situ hybridization (FISH) analysis of freshly isolated synoviocytes and stimulated or unstimulated cultured FLS was performed using DNA probes specific for chromosome 17, 8, 11, 6, 7 centromeres and the p53-(17p13), c-myc-(8q24), and the retinoblastome gene-1-(13q14) gene locus. In all the patients studied, both RA and OA, concordant signal numbers with the probes recognizing chromosome 17, 8, 11 centromeres, 17p13, 8q24, and 13q14 were obtained (dual color FISH), indicating that allelic losses or gains of p53, c-myc, or the retinoblastoma gene-1 are not prevalent in fibroblast-like synoviocytes. Using α-satellite DNA probes specific for chromosome 6 or 7, alterations in chromosome number were identified in synoviocytes derived from some patients with both RA and OA. In fibroblast-like synoviocytes, alterations in chromosome number and subsequent selection of chromosomally altered cells may occur in the joints of patients and contribute to the perpetuation of synovitis. 
